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 Abstract  
 
Dietary Intake among Children with Acute Lymphoblastic Leukemia (ALL) 
 
 
Elena J. Ladas 
 
 
Children with acute lymphoblastic leukemia (ALL) are at elevated risk for nutrition-related 
morbidities both during and after therapy. The degree to which dietary intake fluctuates during 
cancer therapy and possibly contributes to the development of nutrition-related morbidities is 
unknown.   This study presents the results of the first prospective study describing changes in 
dietary intake in 667 children undergoing treatment for ALL.  Dietary intake was evaluated with 
a food frequency questionnaire at three timepoints reflecting different intensities of cancer 
therapy: diagnosis (Time 1-no therapy), induction (Time 2- high-dose therapy), and continuation 
(Time 3- low-dose therapy).  Dietary intake was compared to the Dietary Reference Intakes 
(DRIs) and normative data.  Contrary to expectations, total caloric intake in the majority of 
patients exceeded the DRIs with a smaller percentage of patients below the DRI for calories.  
The majority of patients were within the DRI for all other macronutrients with an increase in 
intake of fat at Time 2.  Despite adequate caloric intake, the majority of patients had low dietary 
intakes of calcium, vitamin D, and vitamin E while excess dietary intakes were observed for zinc 
and niacin. For folate, most patients were either below or above the DRI.  In general, dietary 
intakes were reflective of normative data suggesting intakes are not significantly altered during 
treatment for ALL.    This study was successful in identifying priority nutrients for dietary 
intervention and scientific inquiry. The effect of these strategies on the development of nutrition-
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Chapter 1: Introduction 
 
This chapter provides an overview of the background, rationale, and aims of the current study.   
 
1.0 Introduction 
Although relatively rare, childhood cancer is the second leading cause of death among children 
and adolescents in the United States (Center for Disease Control, 2010).  While the incidence of 
childhood cancer has increased, the establishment of research cooperative groups has aided the 
systematic collection of data.  As a result, overall mortality in most developed areas of the world 
has decreased due to advances in research and a better understanding of cancer biology.  Overall, 
five year survival rates for all childhood cancers increased from 58.1% in 1975-77 to 79.6% in 
1996–2009 (National Cancer Institute, 2012).  Improvements in survival have been most 
apparent for acute lymphoblastic leukemia (ALL).  In a little over two decades, overall survival 
for children with ALL has increased from a mere 10%, to over 90% for patients with low risk 
ALL (i.e. standard risk ALL) (National Cancer Institute, 2012).   
 
The rise in the survival rate for childhood cancer is largely, but not solely, attributed to the 
adoption of multi-modal therapy, which include combinations of chemotherapy, surgery, 
radiation, and stem cell transplantation. Research documenting the effectiveness of multi-modal 
therapy has been aided by the development of research consortiums, which increase 
investigators’ access to a large number of patients and provide an assurance of quality to clinical 
data. Research consortiums such as The Children’s Oncology Group (COG) or The Dana Farber 
Cancer Institute (DFCI) are two of the largest research consortiums exclusively focused on the 






from most major universities and teaching hospitals in the United States, Canada, Australia, and 
New Zealand. Prior to the formation of these groups, research focusing on supportive care during 
cancer therapy, which includes nutrition therapy, was limited due to small sample sizes and 
heterogeneous populations comprised of patients with varying cancer diagnoses and treatment 
protocols.    
 
1.1 Background and rationale for the study 
Few clinicians would dispute the importance of providing nutrition support to a child.  Children 
who are malnourished are at increased risk for infection, reduced quality of life, and poor 
neurodevelopmental and growth outcomes (Picot et al., 2012). Epidemiologic data from 
developing countries in which children with cancer often present with overt malnutrition at 
diagnosis, show that poor nutrition status correlates with reduced survival (Sala et al., 2012).  
Recent studies have found that remediation of malnutrition, defined by anthropometric measures, 
has been one of many supportive care strategies leading to improved survival rates for children 
with cancer residing in developing countries (Antillon et al., 2012).  
 
Clinical studies have also demonstrated that children who are well-nourished at diagnosis often 
become malnourished during therapy due to the side effects of the drugs administered to treat the 
cancer (Brinksma et al., 2012).  The incidence and severity of malnutrition is associated with the 
class and dose of chemotherapy and radiation (Ladas et al., 2005).  For example, methotrexate is 
a chemotherapy agent that is used for the treatment of many childhood malignancies including 
ALL, solid tumors, and Non-Hodgkin’s Lymphoma.  At low doses, methotrexate can cause mild 






methotrexate is associated with severe mouth sores, nausea and vomiting, and loss of appetite.  
These nutrition-related side effects have an adverse effect on nutrition status and may lead to 
mild or severe malnutrition.  In moderate to severe cases of malnutrition, enteral feeds or total 
parenteral nutrition is required to ensure minimum intake of nutrients.  Unfortunately, this is not 
a routine part of supportive care due to the lack of evidence documenting the importance of 
nutrition therapy in children and adolescents undergoing treatment for cancer.   
  
Children and adolescents with ALL may also become overweight or obese as a consequence of 
therapy (Withycombe et al., 2009).  Prolonged exposure to steroids may contribute to the 
development of obesity during and after cancer therapy.  Children with cancer are also at 
increased risk for heart disease, metabolic syndrome, and hypertriglyceridemia due to the therapy 
administered for the treatment of ALL (Hudson et al., 2003), risk factors that may be exacerbated 
by the presence of obesity.  Managing both ends of the nutrition spectrum in children with ALL 
is an ongoing challenge for clinicians.    
 
The rationale of the current study was to provide an understanding of dietary intake patterns in 
children with ALL over the course of therapy.  Findings are intended to identify potential areas 
of high priority for nutrition intervention. 
 
1.1.a Initial Studies Reporting on Nutrition Status in Children with Cancer 
Clinical studies from the late 1970s provide the first line of evidence of the importance of 
nutrition support in children and adolescents with cancer.  These studies examined the feasibility 






et al., 1979; Filler et al., 1977; Rickard et al., 1980; Rickard et al., 1985; Van Eys, 1998; Van Eys 
et al., 1980).  Filler et al. performed one of the first small pilot studies in 41 children with cancer 
and demonstrated that no adverse events were associated with the administration of total 
parenteral nutrition during cancer therapy (Filler et al., 1977). Subsequent studies provided 
details on the timing and severity of malnutrition, and its effect on therapy-related side effects 
and survival.  Many of these studies were retrospective reviews performed with small sample 
sizes, mixed cancer diagnosis and treatment regimens, and relied on varied definitions of 
nutrition assessment (Brinksma et al., 2012).  Despite these limitations, some clear patterns 
emerged.  First, the provision of nutrition therapy was found to be safe among children with 
cancer since neither enteral or total parenteral nutrition were associated with an increase in 
adverse events (Filler et al., 1979; Rickard et al., 1982; Van Eys, 1982).  Second, malnutrition 
was associated with an increase in therapy-related side effects such as infection and 
myelosupression (bone marrow suppression) (Rickard et al., 1986; Van Eys et al., 1980).  
Finally, well-nourished patients reported improved quality of life compared to undernourished 
patients (Van Eys, 1998).  
 
1.1.b Recent Studies Reporting on Nutrition Status in Children with Cancer   
The measurement of nutrition status in children and adolescents may be performed utilizing a 
range of indices that include: (1) assessment by history, (2) clinical assessment, (3) 
anthropometric assessment, and (4) laboratory assessment (American Academy of Pediatrics et 
al., 2004).  Pre-existing risk factors, either medical or socioeconomic, medical conditions, 
prolonged hospital admissions, and age of the child will determine the best index.  According to 






data is sufficient in denoting the nutrition status of most children and adolescents (American 
Academy of Pediatrics et al., 2004).  For children with cancer, the current standard of care in 
denoting nutrition status is limited to anthropometrics with the use of diet recalls or food records 
only when clinically indicated (Mosby et al., 2009).  In the peer-reviewed literature, 
classification of nutrition status is reported utilizing anthropometric measures with few authors 
reporting on dietary intake (Brinksma et al., 2012).  
 
In children with cancer, studies performed within the last decade have improved the 
understanding of the relationship between nutrition status and therapy-related side effects and 
survival by performing studies in patients with a single cancer diagnosis and receiving similar 
cancer treatment regimens.  Lange et al. was one of the first investigators to report on the effect 
of nutrition status on survival in 768 children with acute myeloid leukemia (Lange et al., 2005).  
This was one of the first studies conducted in a homogenous patient population with a large 
sample.  This study found a significant difference in survival among children who were 
underweight (body mass index (BMI) ≤ 10th %) or obese (BMI ≥ 95th %) compared to normal 
weight children.  Subsequent studies confirmed these results.  Hingorani et al. reported that a low 
BMI at diagnosis was associated with increased slough (dead tissue surrounding a wound), 
wound infections, and arterial thrombosis in children with osteosarcoma (n=498) (Hingorani et 
al., 2011).  A large study performed among 2,057 children with high-risk ALL found that 
patients who were underweight (BMI < 5th percentile) or obese (BMI > 94th percentile) 
experienced increased therapy-related side effects due to cancer therapy (Orgel et al., 2011).  The 
study also found that patients who were underweight for the majority of treatment had lower 






rhabdomyosarcoma, greater than ten percent weight loss at 24 weeks was associated with more 
therapy-related side effects and hospital days (Burke et al., 2012).  Patients who were obese 
(BMI > 94th percentile) at diagnosis had inferior failure free survival (the interval from diagnosis 
to progression or death) but not overall survival (the interval between diagnosis and death).  
Children and adolescents who were underweight (BMI <5th percentile) at diagnosis had 
borderline inferior failure free survival compared to those who were within a healthy weight 
range.   
 
These were among the first studies to suggest that both patients who were underweight and 
overweight have increased therapy-related side effects and reduced survival compared to 
children who were within a healthy weight range.   However, these studies could be criticized in 
that most have relied only on height, weight, or BMI percentile as a proxy for nutrition status.  
These indices are limited in denoting nutrition status since cancer or side-effects associated with 
cancer therapy can falsely elevate anthropometric measures such as when edema or high tumor 
burden falsely elevate a patients’ weight (Mosby et al., 2009). 
 
While studies utilizing more sensitive markers of nutrition status such as skinfold tests may 
result in more consistent findings, (Barr et al., 2011) they are still limited in that dietary intake of 
essential nutrients are not considered in the assessment of nutrition status. Ideally, a 
comprehensive assessment of nutrition status that includes both diet and anthropometric 
measures would provide clinicians with the most useful information in determining the nutrition 







1.1.c Studies Exploring Dietary Intake among Children with ALL  
The few studies that have reported on dietary intake during cancer therapy have been performed 
primarily with small sample sizes or among patients treated with outdated treatment regimens.  
Two were performed in children with ALL and two studies were reported in children with 
heterogeneous cancers.    
 
Bond et al. used weighed food records to describe dietary intake in 26 children (age range: 5-16 
years; male=16/ female=10) with mixed cancer diagnoses compared to 26 unmatched healthy 
controls (Bond et al., 1992).  Among children with ALL, energy intake was similar to controls 
groups (Patients: Mean=1822 kcal per day (SEM=140)) Controls: (Mean=1860 kcal per day 
(SEM=62)) and was below the recommended dietary allowance (RDA) in both groups.  This 
finding was similar among children with solid tumors.  In a small cross sectional study, food 
frequency questionnaires were used to describe dietary intake among 16 (male=7/female=9) 
children with varying types of cancer between 6-15 years of age compared to 19 age- and 
gender-matched controls (Galati et al., 2011).  Dietary intake of calories, fat, and carbohydrate 
were similar between the groups. However, in comparison to controls, children with cancer had 
lower intakes of protein (P=0.027), zinc (P=0.01), phosphorous (P=0.038), riboflavin (P=0.013), 
and B12 (P=0.00) and higher intakes of potassium (P=0.017).   
   
Among children with ALL, Delbecque-Boussard et al. measured dietary intake at four timepoints 
during therapy in 15 children (age range: 2-16 years/gender-NR) and 15 age-matched controls 
(Delbecque-Boussard et al., 1997).  At each of the four timepoints, the caloric intake of children 






RDA.  Dietary intake of protein at the four timepoints was over two times the RDA among 
children with ALL, yet below protein intakes reported by controls. The difference in the 
methodology in collecting dietary intake between the two groups, a 24-hour recalls in the 
children with ALL and 7-day food records in the controls, limits the interpretation of these 
results.  Finally, in another small study dietary intake and body composition was evaluated in 16 
children (age range: 2-15 years; male=8/female=11) undergoing treatment for ALL (Halton et 
al., 1998).  Dietary intake was measured with a 3-day food record.  In the majority of children, 
total calorie intake was above the Canadian Recommended Nutrient Intake (RNI)).  Protein 
intake was greater than 100% of the RNI in nearly all children.  This was the first study to report 
caloric intake in excess of the recommended values among children with ALL.              
 
Overall, these studies suggest that the dietary intake of children with cancer may be under or 
over the recommended values for calories with no definitive trends identified. Based upon two 
small studies in children with ALL, protein intake appears to exceed recommendations.  The 
studies must be interpreted with caution considering their small size, multiple confounding 
variables such as diagnosis, phase of therapy, or type of treatment were not considered in these 
studies.  These limitations underscore the need for prospective studies exploring dietary intake in 
patients with a single cancer diagnosis at consistent timepoints to explore the effects of cancer 
therapy on dietary intake and how they compare to normative and recommended values.  
 







To date, there have not been any studies that have comprehensively evaluated overall diet on 
therapy-related side effects.   However, there have been several studies that have explored 
dietary intake or serum assessment of select nutrients and the frequency and severity of side 
effects.  Micronutrients of interest have been bone-metabolizing nutrients due to bone 
morbidities associated with treatment for ALL; antioxidants due to the theoretical effect that 
antioxidant properties may minimize therapy-related side effects, and B vitamins due to the 
administration of anti-folate medications for the treatment of ALL.  Comprehensive reviews of 
these nutrients have been previously published (Ladas et al., 2004; Robien, 2005; Tylavsky et al., 
2010).  Select studies are highlighted below.   
 
One study explored the effect of dietary intake of antioxidants on therapy-related side effects and 
survival in children with cancer.  This was a prospective study in 103 children with ALL (age 
range: 2.1-15.1 years; male=60/female=43) and collected dietary intake with both a 24-hour 
recall and FFQ at three timepoints during therapy (Kennedy et al., 2004).  The authors found 
children with higher, compared to children with lower, dietary intake of beta-carotene and 
vitamin C experienced reduced hematologic or non-hematologic side effects (P=0.04), lower risk 
of hematologic or non-hematologic side effects (P=0.01), fewer delays in the administration of 
scheduled chemotherapy (P=0.04), and fewer days spent in the hospital (P=0.04).  Children with 
higher dietary intakes of vitamin A were more likely to have a slow response to treatment 
(P=0.05), whereas those with higher vitamin E intakes were more likely to have a rapid response 
to treatment (P=0.05). The authors concluded poor dietary intake of select nutrients was 






highlight the need for dietary counseling during cancer therapy so as to potentially minimize the 
risk of side effects due to poor dietary intake of select nutrients. 
 
To date, no studies have explored dietary intake of bone-metabolizing nutrients during cancer 
therapy. One cross-sectional study explored bone-metabolizing nutrients in survivors of ALL.  
Investigators found that the majority of patients were below the RDA for calcium, vitamin D, 
potassium, and magnesium (Tylavsky et al., 2010).  Whether reduced intakes accelerate the 
development of bone morbidities associated with cancer therapy or if children with cancer are 
more susceptible to bone morbidities irrespective of dietary intake is unknown.  A better 
understanding of dietary intake of bone-metabolizing nutrients during all phases of treatment is 
sorely needed to better understand which patients may be at risk for bone morbidities and 
warrant intervention.   
 
To date, no studies have explored dietary intake of B vitamins during cancer therapy in children 
with ALL.  Folate, in particular, is a nutrient of high interest due to the inclusion of methotrexate 
(an anti-folate drug) for the treatment of ALL.  While patterns of dietary folate alone may not be 
relevant, dietary intake of folate within the context of serum folate and polymorphisms in folate 
metabolizing enzymes are of clinical interest (Robien, 2005).  Some studies have suggested a 
role of B vitamins in the development of neuropathy, a side effect of therapy for ALL (Abbas et 
al., 1997; Ang et al., 2008).  These studies have focused on serum levels of B nutrients and 







Taken together, studies to date suggest that nutrition status, either measured by BMI or dietary 
intake, may influence the development of therapy-related side effects.  Children and adolescents 
at weight extremes appear to have reduced survival when compared to children within a healthy 
weight range.  The few studies that have reported on dietary intake have done so in a limited 
fashion focusing on select nutrients of interest rather than a comprehensive evaluation of diet.   
 
1.1.e Current Dietary Guidelines for Children and Adolescents with Cancer  
Current clinical nutrition practice in children and adolescents with cancer is primarily based 
upon the expert opinion of the physician, dietitian, and nurse with efforts focused on the 
treatment of malnutrition or obesity rather than the prevention. Little consideration is given to 
the broader scope of nutrition therapy that includes dietary counseling on healthy dietary 
patterns, especially during cancer therapy. Optimizing cancer care includes placing emphasis on 
all aspects of supportive care interventions that include nutrition therapy (Ladas, 2009).  This is 
especially important for the child with cancer as clinicians have the additional challenge of 
supporting growth and development while delivering the recommended doses of anticancer 
therapy.  Clinicians should be compelled to include this into the scope of cancer care however 
the paucity of data has prevented nutrition therapy from being systematically incorporated into 
the care of every child and adolescent with cancer.    
 
Presently, dietary guidelines for children during and after cancer therapy are generally centered 
on the prevention of cancer and are reflective of those guidelines set forth for healthy children 
(www.choosemyplate.gov) without a history of cancer or for survivors of adult malignancies 






2003).  These guidelines include the importance of weight management, fruits and vegetables, 
whole grains, and lean protein however do not address potential nutrient deficiencies that may 
develop as a result of cancer therapy.  Moreover, the guidelines are not modified to reflect the 
increased risk of nutrition-related conditions such as heart disease, metabolic disease, or obesity 
that are widely prevalent among survivors of childhood cancer. Often, nutrition 
recommendations mirror those for healthy children, are extrapolated from other pediatric 
conditions, or are adapted from the adult literature.  It is reasonable to hypothesize that nutrition 
therapy guidelines may require modification for children with cancer especially given the 
extensive duration of cytotoxic therapy and myriad of nutrition-related side effects that are 
frequently encountered by children with cancer.  However, before epidemiologic studies 
investigating the benefit of nutrition intervention for children receiving cancer therapy can be 
undertaken, an understanding of the unique nutritional needs of this vulnerable population is 
warranted.    
 
1.2 Purpose of Study  
The present study builds upon the existing science by exploring dietary intake among children 
with ALL representing a large population of children with a single cancer diagnosis on a 
standard treatment protocol.  This study will evaluate changes in the dietary intakes of 
macronutrients and micronutrients at three different timepoints in therapy: Time 1 (no therapy), 
Time 2 (high dose therapy), and Time 3 (low dose therapy).  This study is the first study to 
explore the magnitude of variation in dietary intake in a relatively large, homogenous pediatric 
patient population.  This study will be the first to describe how variations in dietary intake differ 






the Dietary Recommended Intakes (DRI) set forth by the National Academy of Science.  The 
information obtained from this study will be used to make recommendations for the optimal 
timing and priority areas in which subsequent nutrition interventions may be designed and tested 
for children and adolescents with ALL.   
 
1.3 Statement of research questions or hypothesis  
This study aims to evaluate the following research objectives:  
 
Study Objective 1:  To describe macronutrient and micronutrient dietary intakes at three different 
time points: Time 1 (diagnosis (no therapy); Time 2 (end of induction (high dose therapy)); Time 
3 (continuation (low dose therapy)) in children undergoing treatment for acute lymphoblastic 
leukemia. 
 
Hypothesis: Dietary intake will fluctuate over the course of ALL cancer therapy due to 
different intensities in therapy (high dose compared to low dose).  Lower intakes will be 
observed during high dose therapy (induction); higher intakes during the low dose phase of 
therapy (continuation). 
 
Study Objective 2:  To compare mean dietary intake of macronutrients and micronutrients at 
three different time points: Time 1 (diagnosis (no therapy); Time 2 (end of induction (high dose 
therapy)); Time 3 (continuation (low dose therapy)), in children undergoing treatment for acute 
lymphoblastic leukemia to dietary intakes of children reported in National Health and Nutrition 







Hypothesis:  Children undergoing treatment with ALL will have dietary intakes that are 
significantly different from that of normative values provided by NHANES due to the 
diagnosis of cancer even during a period of low dose chemotherapy.          
  
Study Objective 3:  To describe the percentage of children undergoing treatment for acute 
lymphoblastic leukemia that are below, meet, or exceed the dietary recommended intakes for 
macronutrients and micronutrients  at three different timepoints in therapy: Time 1 (diagnosis 
(no therapy)); Time 2 (end of induction (high dose therapy)); Time 3 (continuation (low dose 
therapy)).    
 
Hypothesis:  A larger proportion of patients with ALL will be under or exceed Dietary 
Reference Intakes compared to patients meeting the Dietary Reference Intakes.  Differences 
will be observed between phase of therapy and age with most deficiencies being observed 
during the initial phases of therapy (Time 1 and Time 2) and excesses observed during later 
phases due to lower dose therapy (Time 3) .       
 
1.4 Significance of Study 
A better understanding of variations in dietary intake during cancer therapy and the degree to 
which children deviate from the DRIs is a necessary first step in developing standardized 
guidelines for clinical intervention that are evidence-based rather than derived from clinical 
experience. Understanding the degree to which intakes are below or exceed the DRIs will aid in 






treatment.  This study is the first to explore how diet intake in pediatric patients with ALL 
compared to two routinely referenced dietary data sets: 1) National Health and Nutrition 
Examination Survey which provides normative values reflecting intakes of children residing in 
the United States, and 2) The Dietary Reference Intakes which are reference values used to 
assess and plan for individual and group dietary goals.   The results of this study will provide a 
description of dietary intake at various timepoints in therapy.  An understanding of dietary intake 
that is above or below the recommended values may be beneficial in ultimately designing future 
nutrition interventions that may minimize therapy related side effects and maximize cancer 
survival.   
 
1.5 Scope and Delimitations  
This study focuses only on children and adolescents with cancer that received treatment at a 
center that is part of the Dana Farber Cancer Consortium. The results of this study are limited to 
the demographics of the participating centers and to children and adolescents with ALL.   
 
1.6 List of Abbreviations  
 
ADMR- Acceptable macronutrient distribution range  
ALL- Acute lymphoblastic leukemia 
AML- Acute myeloid leukemia 
ANOVA- Analysis of Variance  
BIA- Bioelectrical impedance assay  
BMI- Body mass index 






DFCI- Dana Farber Cancer Institute 
DRI- Dietary Reference Intakes 
HSFFQ- Harvard food service food frequency questionnaire 
FFQ- Food frequency questionnaire  
MUAC- Mid upper arm circumference 
NHANES- National Health and Nutrition Examination Survey 
NFCS- Nationwide Food Consumption Survey  
NR- Not reported 
RBW- Relative body weight percentage  
RDA- Recommended Dietary Allowance  
REE- Resting energy expenditure 
RNI- Recommended Nutrient Intake  
TPN- Total parenteral nutrition  
TSF- Triceps skinfold test 
WFH- Weight for height  














Chapter 2: Literature Review 
The following chapter will provide a comprehensive review of the published literature describing 
nutrition metabolism, nutrition status, and dietary intake in children and adolescents with cancer.  
A focus on the effect of nutrition status on therapy-related side effects and survival will be 
presented as well as the current clinical guidelines supporting nutrition practice in children with 
cancer.      
  
2.0 Acute Lymphoblastic Leukemia  
Childhood cancer is the second leading cause of death in the United States in children between 
the ages of five to fourteen, following accidental deaths (Center for Disease Control, 2010).  
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for 
23% of children diagnosed with cancer under the age of 15 (National Cancer Institute, 2002).  
Since 1975, significant increases in the five-year survival rate for ALL have been observed.  
Reasons for improved survival are targeted central nervous system therapy, alterations in length 
of therapy, combination of drugs, advances in supportive care, identification of novel prognostic 
factors, and risk stratified therapy.  Overall survival for low risk ALL is 90% whereas survival 
for high risk ALL is 70% (National Cancer Institute, 2012).  
 
Although no risk factor is identified in most cases of ALL, prenatal exposure to x-rays, postnatal 
exposure to high doses of radiation, Down syndrome and other genetic conditions, and inherited 
genetic polymorphisms are known risk factors for the development of the disease (Wiemels, 






are black and is most common among Hispanic children (Goggins et al., 2012).  Slightly more 
males than females are diagnosed with ALL with improved survival among females.  A full 
review of the risk factors and their effects on treatment outcomes has been reviewed elsewhere 
(Stanulla et al., 2009).   
 
Children with ALL are categorized into two main risk groups, low risk (also referred to as 
standard risk) and high risk.  According to some protocols, children may be classified as very 
high risk.  Classification of risk category is contingent upon features at diagnosis such as age, 
white blood cell count, and if the cancer has spread to the central nervous system.  Diagnostic 
features associated with standard risk ALL are: children between the ages of 1-9 years old at 
diagnosis, a white blood cell count less than 50,000/µL, and precursor B-cell immunophenotype.  
Failure to respond to therapy within the first phase of therapy (referred to as the induction phase) 
may result in reclassification into very high risk.   
 
2.0.a Treatment for ALL 
Treatment for childhood leukemia typically consists of chemotherapy and may include 
administration of radiation for a sub set of patients including those with leukemia in the central 
nervous system.  As per the Dana Farber Cancer Institute (DFCI) treatment protocol (the 
protocol relevant to the current investigation), treatment for ALL is divided into six phases of 
therapy each of which delivers high- or low-dose chemotherapy over a two year period.  The 








Upon diagnosis with ALL, patients immediately begin on a 3-day course of steroids.  The second 
phase of therapy, referred to as the induction phase, delivers high dose chemotherapy and its 
purpose is to kill the leukemia cells and put the patient in remission.  The third phase of therapy 
is the consolidation phase of therapy and continues to deliver high dose chemotherapy to kill any 
remaining leukemia cells.  The final phase of therapy is the continuation phase of therapy in 
which cancer therapy is administered in lower doses than those used in earlier phases of therapy. 
The phase of therapy varies in length and can be a minimum of 32 days (induction phase) to 15 
months (continuation phase).  After the continuation phase of therapy, children and adolescents 
have completed treatment for ALL.   
   
2.0.b Therapy-Related Side Effects of Treatment for ALL 
Phases of therapy that deliver higher doses of chemotherapy (Phase 2, 3, 4, and 5) are associated 
with increased frequency and severity of therapy-related side effects that may elevate the risk of 
developing malnutrition.  Therapy-related side effects of cancer therapy are graded by a 
standardized five-point Likert grading scale developed by the National Cancer Institute that 
range from mild to death (National Cancer institute, 2010).  Grading of a therapy-related side 
effect is based upon a standard set of clinical criteria that is a component of the clinical 
assessment of the patient.  The type and severity of side effect will depend on the class of drug, 






are neuropathy (pain in the nervous system), fatigue, alopecia (loss of hair), and myelosupression 
(bone marrow suppression).  Of the drugs used to treat ALL, many of them may cause therapy-
related side effects that can reduce the patient’s ability to maintain dietary intake either through 
affecting an individual’s desire to eat or making eating difficult, these types of side effects are 
often denoted as nutrition-related side effects.  Some of the most common nutrition-related side 
effects that affect dietary intake throughout cancer treatment are constipation, loss of appetite, 
weight loss, weight gain, mouth sores (open sores in the mouth), and nausea and vomiting.  
Drugs administered during the treatment of ALL that are associated with nutrition-related side 
effects include cytarabine (nausea, vomiting, mouth sores, diarrhea), dexamethasone (appetite 
stimulant, hyperglycemia), dexrazoxane (constipation), doxorubicin (mucositis), etoposide 
(nausea, vomiting, diarrhea, mucositis, anorexia), 6-mercaptopurine (nausea, vomiting, 
mucositis), methotrexate (mucositis, nausea, vomiting), and vincristine (neuropathy (loss of deep 
tendon reflexes and muscle weakness), pain).  Combined, these may lead to either excess or 
reduced dietary intake.  A summary of drugs, doses, and associated nutrition-related side effects 








While there are a number of nutrition-related side effects encountered by children undergoing 
treatment for ALL, their cumulative effects on aspects of nutrition status such as energy 
metabolism, height, weight, or dietary intake are largely unknown.  Moreover, the degree and 
direction (increased or decreased) at which either cancer therapy or the associated side effects 
impact dietary intake in children with ALL is also unknown.  It is unclear whether children and 
adolescents with ALL are meeting nutrition guidelines or whether they are experiencing 
profound deficiencies or excesses in dietary intake throughout therapy.  
 
2.1 Overview of Cancer on Nutrition Metabolism  
Understanding alterations in nutrition metabolism that may be caused by a diagnosis of cancer is 
necessary for the development of dietary guidelines.   Both preclinical and clinical studies 
suggest that cancer cells induce changes in energy and nutrient metabolism in the patient with 
cancer in order to foster cancer cell growth (Torosian et al., 1986).  Identification of aberrations 
in nutrient metabolism have led to the use of chemotherapy agents targeting micronutrient 
metabolism or specialized diets as a component of anticancer treatment.  For example, the 
understanding that cancer cells require folate to support cell division led to the use of antifolates.  
This class of chemotherapy agents interferes with the uptake of folate in rapidly dividing cells 
thereby causing cell death in cancer cells.  Methotrexate is an antifolate agent and the most 
widely used anticancer medication.  Methotrexate inhibits cancer cell growth by inhibiting the 
enzyme, dihydrofolate reductase, which prevents the conversion of folic acid to tetrahydrofolic 
acid, a cofactor in the metabolism of many amino acids and nucleic acids.  Alterations in 
carbohydrate, fat, and protein utilization have also been observed among individuals with 






to the discovery of l-asparaginase, a drug that inhibits the breakdown of the amino acid 
asparagine preventing uptake from the tumor cell.    Finally, the observation that tumor cells 
preferentially uptake glucose for functioning led to the use of low carbohydrate diets for the 
treatment of certain types of cancer (Klement et al., 2011; Nebeling et al., 1995).    
 
2.1.a  Overview of the Effect of Cancer on Carbohydrate Metabolism 
The role of carbohydrate in cancer growth is embedded in the early work of Otto Warburg, who 
discovered that cancer cells preferentially underwent glycolysis for energy production, even in 
the presence of oxygen (Klement et al., 2011).  Now termed the Warburg effect, this observation 
has become one of the most consistent hallmarks of cancer (Hanahan et al., 2011).  Most of the 
investigations observing the effect of tumor cells on carbohydrate metabolism have been 
completed in animal models and have not been replicated in clinical studies.  Animal models 
suggest that glucose intolerance is multifactorial and is associated with the use of insulin, 
increased gluconeogenesis, and increased use of the Cori cycle resulting in elevated levels of 
lactate in the body (Berchard et al., 2002; Van Eys, 1985).  Increased lactate levels may also be 
the result of the tumor cell itself producing lactate (Van Eys, 1985).  The aberrations in 
carbohydrate metabolism has been linked to an increase in the release of cytokines such as 
interleukin 6, which has been shown to stimulate gluconeogenesis and lactate acid formation 
(Argiles et al., 1999).   
 
The clinical implications of carbohydrate metabolism on cancer cell growth and survival of 
cancer in adults and children with cancer is less understood.  In women with breast cancer, 






Garza et al., 2012).  The role of elevated glucose levels in children with cancer is not known.  
Increased levels of glucose have been associated with increased infections in children with ALL 
(Sonabend et al., 2008).   Insulin resistance may be a factor contributing to obesity among 
survivors of ALL, (Chow et al., 2012) however elevated levels of glucose does not appear to be 
related to obesity (Bang et al., 2012).  Case series have reported on the effect of low 
carbohydrate diets for the treatment of brain tumors in children (Nebeling et al., 1995).  
However, randomized clinical trials have not been reported most likely due to the difficulty in 
administering a low carbohydrate diet to children and adolescents.  Additional research is clearly 
needed in this area so as to better define if carbohydrates may be a potential therapeutic target in 
the treatment or management of cancer.              
 
2.1.b  Overview of the Effect of Cancer on Fat Metabolism 
Body fat depletion, increased lipolysis, and decreased lipogenesis has been the hallmark of fatty 
acid metabolic aberrations in patients with cancer (Shils et al., 1999).  This generally correlates 
with increased plasma triglycerides and loss of body fat in the tumor- bearing host.  Investigators 
have observed increased lipoprotein lipase activity, hormone-sensitive lipase, and liver 
lipogenesis (Shils et al., 1999).  This is often result in aberrant lipid profiles that may include 
decreased high-density lipoproteins and increased very low-density lipoproteins.  As with 
carbohydrate metabolism, these anomalies may be precipitated by production of certain 
cytokines, specifically tumor necrosis factor, interleukin 1, interleukin 6, and interferon α 
(Argiles et al., 1999).  No clinical trials have been conducted targeting aberrations in fat 







2.1.c  Overview of the Effect of Cancer on Protein Metabolism 
Protein metabolism has been the most thoroughly researched of the macronutrients and findings 
from these investigations have led to the development of effective anticancer agents for the 
treatment of certain malignancies including ALL.  The development and use of the anticancer 
agent L-asparaginase stemmed from that finding that T-cell ALL cells heavily depend on 
asparagine for cellular reproduction.  The use of L-asparinganse reduces the availability of 
aspargine to T-cell ALL cells inducing cell death.  Asparaginase is now a backbone drug for the 
treatment of ALL and T-cell lymphoma.   
 
Protein metabolism is affected by tumor burden and the diagnosis of the patient.  The primary 
source of proteins in the human body is skeletal muscle thus decreased muscle mass 
accompanies increases in protein turnover that may be stimulated or inhibited by humoral 
factors.  Humoral factors are primarily cytokines that affect neuropeptides that promote or inhibit 
appetite, stimulate metabolic alterations in the human body, or act through an unknown 
mechanism.  The most thoroughly researched cytokines in regard to cachexia are tumor necrosis 
factor (TNF), interleukin-6 (IL-6), interferon-γ (IFN-γ), leukemia inhibiting factor (LIF), and 
ciliary neurotrophic factor (CNTF).  Cytokines such as tumor necrosis factor has been shown to 
stimulate proteolysis (Argiles et al., 1999).  Investigators have found that protein depletion may 
be a result of both muscle breakdown and decreased rates of synthesis; however, the relative 
contribution of these abnormalities is unknown.  It is likely that protein metabolism is affected 
by tumor biology and may vary slightly depending on the biological characteristics of the tumor.   
 






Tumor cells have an inherent ability to alter the energy metabolism of the host.  Alterations in 
energy metabolism have been suggested as one of the causes of severe weight loss in patients 
with cancer.  One clinical study in children with sarcomas suggests that alterations in REE may 
precipitate the onset of cachexia (Peacock et al., 1987).  However, there are limitations to 
evaluating alterations in energy expenditure in children with cancer.  Formulas to estimate 
energy intakes in children who are malnourished have not been thoroughly designed and tested.  
Therefore, clinicians extrapolate the formulas reflective of healthy children to those of children 
with cancer.  The use of these equations in children and adolescents who are with a serious 
medical condition may underestimate individual dietary needs (Galati et al., 2011).   Most of the 
published studies exploring energy expenditure is limited to older children and is not reflective 
of younger children.    Understanding changes in activity must also be controlled for as reduced 
REE may also be explained by more sedentary behavior during cancer treatment.    
 
Although limited, the available studies reporting on REE in children with cancer have attempted 
to control for each of the aforementioned variables to varying degrees.  In one of the first studies 
exploring energy expenditure and nutrient turnover, Kien and Camitta studied rates of whole 
body protein synthesis and breakdown by indirect calorimetry in children with leukemia or 
lymphoma (age range 3-14 years; gender- NR) at diagnosis and compared the results to reference 
values (Kien et al., 1987).  The authors found energy expenditure was 50% higher in cases 
compared to reference values.  Protein breakdown and synthesis were significantly related to 
basal metabolic rate (r= 0.925, P< 0.001; r = 0.91; P< 0.01, respectively), which may be related 
to increased energy expenditure.  This study is often referenced as support that children with 






limit the interpretation of the results (Bond et al., 1992).  The study measured basal metabolic 
rate for a short period of time (five minutes) during sleeping hours and the timing of the 
administration of chemotherapy was not controlled for in the study. Comparison of cases to 
controls was not reported.       
 
Stallings et al. conducted a subsequent study that addressed many of the weaknesses in the study 
completed by Kein and Camitta by performing measurements for 60 minutes and controlling for 
disease status and the administration and phase of chemotherapy (Stallings et al., 1989).  REE 
was evaluated at diagnosis, Day 7 and Day 14 of induction therapy in nine children with ALL 
(age range 6-15 years/male=3;female=6). The authors found that before the initiation of 
chemotherapy, patients with a higher tumor burden (Group 1) had a significantly different REE 
(Mean kcal 1951) when compared to children with lower tumor burden (Group 2; Mean 1222 
kcal), P<0.02.  Percent predicted REE (131% of predicted; P<0.004) was higher in the group 
with higher tumor burden compared to the group with low tumor burden (96% of REE); however 
this difference was no longer apparent at Day 7 or 14 thus likely reflecting disease status.  
Carbohydrate utilization increased significantly from diagnosis to Day 7 (P<0.009) and fat 
utilization decreased (P<0.009) but these differences were no longer apparent at Day 14.  The 
thermic effect of food, the amount of energy an individual expends to process and metabolize 
food, increased over the study (P<0.016) and the thermic effect of food as a percentage of REE 
also significantly increased (P< 0.026) in all patients.     In a later study, this same group of 
investigators obtained energy assessments in eight children with ALL (age range 7-18 
years/male=5; female=3) in the final three months of chemotherapy (continuation phase) 






mercaptopurine or methotrexate infusion.  Utilization of fat increased after methotrexate, but not 
after 6-mercaptopurine.  No effects were observed on carbohydrate or protein utilization.  The 
findings of these two studies provide insight as to whether changes in nutrient metabolism and 
REE are a result of 1) the cancer cell itself, 2) the action of chemotherapy agents on host 
metabolism, or 3) tumor burden (Vaisman et al., 1993).  The study suggests that alterations in 
REE may be more strongly related to tumor burden, as demonstrated by REE resuming to normal 
by Day 14 of therapy and that reducing tumor burden through the administration of anticancer 
therapy restores metabolic activity to rates prior to the development of a tumor.  The variations 
in substrate utilization may be related to the administration and dose of chemotherapy agents, 
particularly the role of high-dose steroids during the induction phase of therapy.  Subjects did not 
receive steroids in the latter study.     
 
Reilly et al. explored the changes in resting metabolic rate during the continuation phase of 
therapy (third year of treatment) in 27 children (age range 7.4-12 years/male=15;female=20) 
with ALL who did not receive cranial radiation and compared them to 27 age-matched controls 
(Reilly et al., 1996).  BMI, weight, and height were collected at diagnosis and two years post 
diagnosis.  No significant differences in resting metabolic rate or respiratory quotient between 
study groups were observed.  There was a significant increase in mean BMI standard deviation 
score +1.0 (95% CI 0.4-1.7, P<0.01) in boys (n=15) and girls (n=17) 1.0 (95% CI 0.3-1.6; 
P<0.01) from baseline to the continuation phase of therapy however it should be noted the 
confidence interval includes the value of one.  This study supports the findings of Vaisman et al. 
in that REE is not altered during the continuation phase of therapy in patients who have not 






dietary intake, REE and dietary intake was found to be reduced in 20 children with ALL who had 
undergone treatment compared to age-matched healthy controls (Reilly et al., 1998).   
 
Although the available studies are limited, these results suggest that aberrations in nutrient 
metabolism and REE may contribute to changes in body weight but other factors such as diet or 
other lifestyle behaviors may also have an active role.  This effect is most notable in patients who 
have not received cranial radiation.  The results of these studies suggest that changes in nutrition 
status are caused by multiple factors of which dietary intake are only one component of a multi-
faceted model that may lead to malnutrition.  Although these studies identified aberrations in 
some biochemical nutrient pathways, their combined effect is still not entirely clear.  These 
studies are able to merely suggest that changes in nutrient metabolism is likely occur during 
cancer therapy and should be recognized when providing nutrition therapy to children with 
cancer.   
 
2.1.e Clinical Conditions Associated with Metabolic Aberrations    
Cachexia has long been a hallmark of cancer therapy in both children and adults and is often 
mistaken for severe malnutrition.  Cachexia is a distinct clinical condition that is associated with 
altered nutrition metabolism in patients with cancer and is most common in patients with 
advanced disease or with heavy tumor burden.  Conversely, severe malnutrition may be 
diagnosed with significant weight loss but is often not associated with alterations in nutrition 
metabolism.  Symptoms of cachexia include reduced appetite, early satiety, weight loss, and 
reduced energy (Langer et al., 2001).  Although cachexia is similar in presentation to starvation 






are hypermetabolic coinciding with a reduction in appetite.  This is evidenced by persistent 
weight loss with a marked reduction in total calories.  Patients with cachexia often consume as 
little as 10-25% of total caloric needs.  In contrast, patients experiencing starvation have weight 
loss that is accompanied by a conservation of energy metabolism and a robust appetite.        
 
Most of the research investigating the process of cachexia has been conducted in animal models 
with few studies replicated in human trials.  Cachexia is a complicated physiological process that 
varies by stage and site of the tumor.  Investigations have identified both humoral and tumor-
secreting factors as primary inducers of the cachexia process (Argiles et al., 1999; Argiles et al., 
2003; Van Eys, 1985).  Humoral factors are primarily cytokines that affect anorexigenic 
neuropeptides, stimulate metabolic alterations in the human body, or act through an unknown 
mechanism.  The most thoroughly researched cytokines in regard to cachexia are tumor necrosis 
factor, interleukin-6, interferon-γ, leukemia inhibiting factor, and ciliary neurotrophic factor.  
The interaction of these factors appear to be related to one another, possibly exerting a 
synergistic effect in the individual with cancer (Argiles et al., 1999).  Individually, tumor 
necrosis factor has been shown to induce cachexia in animal models.  Tumor necrosis factor has 
also been found in the plasma of children with leukemia; however, elevated serum levels do not 
appear to be the cause of the development of cachexia (Saarinen et al., 1990).  Significant strides 
have been made in understanding cytokines such as interferon-γ, leukemia inhibitory factor, 
interluekin-6, administration of antagonists has not been successful in remediating the 
development of cachexia (Argiles et al., 2003; Ramos et al., 2004).  A clear cause and effect 
pathway has not yet been identified for any humoural factor causing cachexia.  Tumor-secreting 






effect is also not clear.  Some of the earliest theorists proposed that tumor-secreting compounds 
induce metabolic abnormalities in the human body thereby resulting in increased metabolic 
activity and decreased appetite however based upon the literature reporting on REE this is likely 
not the sole effect (Theologides, 1976).  Others have suggested tumor-releasing compounds act 
directly on the liver thereby stimulating inefficient production of substrates used for energy in 
the body (Van Eys, 1985).   
     
Laboratory investigations have also revealed that cancer cells release compounds that lead to 
aberrations in the appetite regulating network.  This has been supported by a few small studies 
published in children with cancer (Hagan et al., 2012).  Laboratory investigations have suggested 
that the development of cachexia may be a result of cytokines exerting a stimulant or inhibitory 
effect on appetite, an action similar to that of neuropeptides.  Leptin is secreted by adipose tissue 
and stimulates anorexigenic compounds while simultaneously inhibiting the release of 
neuropeptide Y (appetite stimulant).  It is unknown if cytokines act in an unknown fashion 
mimicking the effects of neuropeptide Y and leptin, or stimulate the neuropeptides directly.  
Alterations in serum levels of leptin have been observed in children with cancer (Karaman et al., 
2010).  Future studies are needed to elucidate the precise mechanism of action.   
 
2.2 Early Studies on Nutrition Status in Children with Cancer  
Initial evaluation of nutrition status and dietary intake among children and adolescents with 
cancer dates back to the 1960’s.  Studies performed in this era explored the use of sterile diets, 
also referred to low bacterial diets or a cooked foods diet, to promote gut sterilization (removal 






radiation) (Moody et al., 2002).  Investigators hypothesized that reducing the risk of bacterial 
exposure through food would reduce the risk of developing an infection.  Study outcomes were 
focused on the incidence of infection and survival with no consideration to the impact of these 
rigorous diets on the nutrition well being of the patient.  Mixed results were reported in these 
trials with later studies reporting that these extreme diets were unnecessary during cancer therapy 
and had no effect on the incidence of infections (Gardner et al., 2008; Moody et al., 2006).    
 
It was not until the late 1970’s that the role of dietary intake and clinical nutrition intervention 
came under scrutiny.  Driving this research were clinicians reporting associations between 
weight loss, reduced tolerance to therapy, poor quality of life, and frustration on behalf of the 
patient and parent without data substantiating these clinical observations (Donaldson et al., 
1981).  It was not until a small pilot in 41 children with cancer was published that medical 
nutrition therapy emerged as a component of supportive care.  Filler et al. was the first to report 
that total parenteral nutrition (TPN) was found to be safe with no adverse events (Filler et al., 
1977).  Prior to this, administration of medical nutrition therapy was limited due to concerns that 
TPN would increase the risk of developing an infection, a life-threatening complication.  
Proponents of nutrition support argued that malnutrition is an independent risk factor for 
infection and by improving nutrition status through nutrition intervention a reduction in the 
incidence of infection may be observed.  This hypothesis served as a catalyst for subsequent 
studies exploring the effect of nutrition interventions on therapy-related side effects, infection, 
and overall survival in children and adolescents undergoing treatment for cancer. 
 






Initial studies systematically evaluating nutrition status explored the safety of TPN over the 
standard of care, which at the time was no nutrition intervention (e.g. no provision of TPN or 
enteral feeding).  In one of the first randomized studies exploring a nutrition intervention in 
pediatric oncology, 35 children (Age=NR/Gender=NR) with heterogeneous cancers were 
randomized to TPN or dietary advice (Van Eys et al., 1980).  Children who were malnourished 
received TPN (n=15) while well-nourished patients (n=20) were randomized to diet advice or 
TPN.  The primary outcome in this study was the effect of TPN on nutrition status and weight 
for height (WFH) (< 80% = malnourished).  Among patients who were well-nourished, two of 
ten patients in the diet advice group and two of ten patients in the TPN group developed 
malnutrition; however, these patients also had progressive disease diminishing the ability to look 
at the effect of TPN.   Dietary intake was 22% and 16% of recommended dietary allowance 
(RDA) for calories and 55% and 34% of protein, in the TPN compared to diet advice group, 
respectively demonstrating the effectiveness of TPN in augmenting dietary intake during cancer 
therapy.  TPN was also effective at enhancing nutrient intake among children and adolescents 
who were malnourished group demonstrated by 45% of calories and 85% of protein delivered by 
TPN.     
 
The study also explored the effect of TPN on tolerance to chemotherapy (measured by incidence 
of side effects), dose reductions, and survival.  Does reductions or dose adjustments during 
cancer therapy are only considered when clinically indicated as reductions in the recommended 
doses of therapy may affect overall survival.  This study found that there were no differences in 
dose adjustments (reductions in therapy due to clinical conditions) between well-nourished 






when all the control patients were compared to all TPN patients, 45% of controls and 22% of 
TPN patients experienced dose reductions (P<0.01) in the first course.  After adjusting for the 
length of treatment, malnourished patients had fewer dose reductions (13 courses per 100 days) 
than well-nourished patients (16 courses adjusted over 100 days) but this difference was not 
significant.  Importantly, this study demonstrated that well-nourished patients in this study 
experienced significantly fewer infections (9/21) compared to malnourished (14/15) (P<0.002).  
The study found 19 episodes of infection in 22 patients who were on TPN and malnourished 
whereas well-nourished patients experienced five episodes of infection (P<0.002).  After 
controlling for the number of days of therapy, the sepsis rate (rate of sepsis was calculated per 
100 patient days), in malnourished compared to well-nourished patients was higher (P<0.001).  
Infections were also higher among malnourished patients on TPN than well-nourished on TPN 
(P<0.05).  It is possible that TPN may elevate the risk of infection in patients who are already 
malnourished and begin treatment with TPN however a causal effect of TPN cannot be 
concluded from this study.  Administration of TPN as a prophylaxis of malnutrition does not 
appear to alter risk of infection as no increased risk of infection among well-nourished patients 
on TPN.    
 
Building upon the findings of van Eys et al., a retrospective review of 244 children with 
heterogeneous diagnosis (age:NR/gender: NR) with cancer was performed (Donaldson et al., 
1981).  Measurement of nutrition status was determined by weight, height, WFH < 80%, and 
albumin. Patients were followed at the time of first referral until death, loss to follow-up, or most 
recent visit.  Poor nutrition status (WFH or low albumin) was significantly correlated with 






diagnosis, no significant relationships were observed.  Nutrition status at time of referral was 
related to subsequent relapse, which was most evident for children with a solid tumor (P=0.007).  
The relationship remained after stratification by stage (P=0.04).  At time of first referral, well-
nourished children with lymphoma (P=0.02) and solid tumors (P=0.03) with localized disease 
experienced improved survival.  Survival of patients with advanced disease did not correlate with 
nutrition status at time of referral.  The authors concluded that a relationship between nutrition 
status and survival may exist among patients with solid tumors.   
 
Despite the inherent weaknesses in the study designs, these landmark studies brought nutrition 
status and intervention into the vernacular of pediatric oncology.  Infections are a life threatening 
complication in children with cancer especially in children undergoing treatment for ALL.  
Infections contribute to 50% of complications and lead to death if intervention is not 
administered immediately.   These were among the first studies to suggest that nutrition status 
may impact therapy-related side effects among children with cancer, especially life threatening 
toxicities such as infection and sepsis.  The studies suggested that malnutrition may be a risk 
factor for increased therapy-related side effects and that minimizing the development of 
malnutrition may improve quality of life over the course of cancer therapy along with improved 
outcomes.  Finally, they demonstrated that feeding a child with cancer, through intravenous 
source, is safe and does not promote cancer cell growth.  Reductions in survival were not 
observed.     
 
Later studies with improved study designs and performed in uniform populations replicated these 






male=9; female-9) with Stage IV neuroblastoma at diagnosis and during the first few courses of 
therapy (Rickard et al., 1983).  Malnutrition was defined as weight loss > 5% of body weight, 
WFH < 5th %, or serum albumin < 3.2 grams per deciliter.  Of the well-nourished group (n=9), 
six children received TPN after failing to maintain nutrition status with oral intake, one patient 
was placed on TPN, and one died.  Children with malnutrition were randomized to TPN (n=4) or 
peripheral parenteral nutrition (n=4) group.  Differences in therapy-related side effects and dose 
reductions were only observed during the first course of therapy.  One of nine children in Group 
1 (well-nourished group) and six of seven children in Group 2 (malnourished group) experienced 
a delay in therapy (P<0.01).  In course 2, Group 1 received 97% +/- 8% of recommended dose 
and Group 2 85% +/-10, (P=0.02). At the 3rd course, Group 1 received 94% +/-10% and Group 2 
82% +/-14% (P=0.07).  When all courses are evaluated together, children in Group 1 received 
more recommended doses compared to Group 2 (P=0.04).  This is an important finding as lower 
than the recommended dose of therapy or delays in the timing of therapy can have an adverse 
effect on survival.  In concordance with van Eys et al., the authors found that response to therapy 
was not related to nutrition status.  However, the number of days to first event (relapse or death) 
was greater for the well-nourished compared to the malnourished (P<0.01) and median survival 
for the well-nourished was 12 months compared to five months for the malnourished (P=0.08) 
suggesting prolonged survival among patients who were well-nourished.  However, change in 
nutrition status over therapy did not impact overall survival at one year.  A follow-up study in 32 
children with Stage III/IV neuroblastoma confirmed these findings (Rickard et al., 1985).    
 






Measurement of nutrition status is variable in children as there are many indices that can be 
applied to categorize patients as malnourished.  Each of these has its strengths and limitations 
(Mosby et al., 2009).  The use of weight alone as a marker of nutrition status is of limited use 
within the context of pediatric oncology as it is frequently altered by hydration status, the tumor 
mass, infection, or an amputation which reduce the sensitivity of weight as an indicator of 
nutrition status (Barr et al., 2011).   Biochemical indices of nutrition status are also of limited use 
in children undergoing treatment for cancer as there is no biochemical marker that is not altered 
by the effects of cancer therapy.  Albumin has limitations as disease status, infections, and 
therapy related side effects reduce the sensitivity and specificity of albumin.  While pre-albumin 
has been promoted as a more sensitive indice of nutrition status, it is not without limitations and 
is not routinely collected in the absence of overt malnutrition.   
 
The commonly reported indice to describe changes in nutrition status include weight, height, 
WFH, BMI, BMI percentile, mid-upper-arm circumference (MUAC), and triceps skin fold (TSF) 
thickness.  The gold standard of nutrition assessment in children with cancer is largely unknown 
however a recent study suggests that skinfold tests are the most sensitive indice for the 
measurement of nutrition status among children with cancer (Barr et al., 2011).  Investigators 
have also relied upon fluctuations in fat and fat free mass to gauge nutrition status (Murphy et 
al., 2010).     While the application of this advanced technology to measure fat versus fat free 
mass is ideal in providing clinicians with a comprehensive understanding of nutrition status, the 
expense required to evaluate body composition limits its use in the clinical setting.  
Unfortunately, there is no unanimous agreement on the gold standard therefore the available 






primary aim was to document the prevalence of malnutrition in children with cancer is provided 
below. 
 
2.3.a Nutrition Status in Children and Adolescents with Solid Tumors 
In a cross-sectional study among 36 patients (age range 4.8-15 years; female=15/male=21) with 
solid tumors, nutrition status was assessed in 19 children during therapy and 17 children in short 
term follow up (1-24 months post completion of therapy) (Schiavetti et al., 2002).  Weight, 
height, BMI, and relative body weight percentage (RBW) were collected on each patient.  In 
patients on therapy, 26% of patients were underweight as per %RBW, and 15.8% according to 
BMI.  36.9% of patients were overweight or obese as per %RBW and 21% as per BMI.   Among 
the patients off therapy, 52.9% were overweight or obese by %RBW and 35.3% as per BMI.  
Both were significantly different than those patients on therapy P<0.05; P=0.05, respectively.  
The correlation between %RBW and BMI was r=0.83, P<0.001, demonstrating differences in 
reporting frequencies between nutrition indices.     
 
2.3.b Nutrition Status in Children and Adolescents with ALL  
Children with ALL rarely present at diagnosis with overt malnutrition in developed countries 
(Ladas et al., 2005).  The development of malnutrition is often a consequence of therapy and 
may vacillate between weight loss and excessive weight gain.  Weight loss is typical during the 
more intensive phases of therapy whereas weight gain is often associated with the continuation 
phase of therapy (Baillargeon et al., 2007; Withycombe et al., 2009).  Weight gain is also a late-






four years after completion of therapy, a phenomenon that has been well-described in the 
literature with an unknown etiology (Oeffinger et al., 2003).    
 
Reilly et al. were one of the first groups to describe weight changes in children diagnosed with 
ALL (Reilly et al., 1994).  This study explored the prognostic impact of WFH in 78 children (age 
range 1.1-13.3 years;male=47/female=31) with ALL.  WFH Z-score at diagnosis was 
significantly related to survival (P=0.012).  This was not influenced by age at diagnosis, 
intensification schedule, white blood cell count, or gender as evidenced by a X2 test.  The 
probability of no relapse within five years of diagnosis was approximately 80% in children with 
WFH Z score > -0.5 and 50% for children with a WFH Z score < -0.5, indicating that the higher 
the deviation from the mean (represented by a Z score of > -.05), the higher the risk of relapse.  
The authors propose that undernutrition may be a nonspecific marker of disease by impairing 
immune function or surveillance and hematopoiesis, reduce the tolerance to anticancer therapy, 
or alter the pharmacokinetics of drugs.             
 
The findings of this study have been followed up by several other retrospective studies.  In a 
follow-up study by the same group of investigators, Reilly et al. explored the prevalence of 
protein-energy malnutrition in 1019 children (age range 0.2-14.9 years; male=767/female=252) 
with standard-risk ALL treated on a uniform protocol (Reilly et al., 1999).  The authors found 
that the observed frequency of BMI standard deviation score < -2.0 (indicated 2 standard 
deviations below the mean) was 7.6% of boys and 6.7% of girls.  The observed frequency was 
significantly different than the expected frequency of 2.3% in both girls and boys (P<0.0001).  






for girls, which was not statistically different than expected.  Evidence revealed that BMI 
standard deviation scores differed significantly from 1.0 (P<0.001 for both sexes). The authors 
concluded that undernutrition at diagnosis is three times higher than expected.  
 
Uderzo et al. evaluated 173 newly diagnosed children with ALL (age range 2-15 years; male=90/ 
female=83) residing in Italy and compared them to 307 children admitted to the hospital for non-
malignant conditions (Uderzo et al., 1996).  Nutrition status was evaluated at diagnosis by 
dietary history, anthropometric measures (weight, height, WFH, MUAC, and TSF), and 
biochemical indices (prealbumin, retinolbinding protein, albumin, ceruloplasmin, mucoprotein, 
transferrin, ferritin, zinc, and C3 complement fraction).  No significant differences were 
observed between the two groups in any of the nutrition indices.   In 25 children with ALL 
between the ages of 1-14 years, nutrition status, defined by WFH, weight, height, albumin, 
MUAC, TSF, was observed at various timepoints in therapy.  The authors did not find any cases 
of malnutrition (Yu et al., 1994).   
 
In one of the only studies describing patterns of weight gain and loss in children with high-risk 
ALL (n=1,638), BMI percentile was found to decrease over the course of therapy (P<0.014 to 
P<0.0001) (Withycombe et al., 2009).  By the continuation phase of therapy, BMI percentile 
increased and was higher compared to diagnosis.   This may be related to prolonged exposure to 
steroids as studies have found an increase in caloric intake coincides with steroid medications 
among children with ALL (Reilly, 2001).  The data presented provides evidence that children 






due to increased caloric intake, reduced energy expenditure, metabolic aberrations, or other 
unknown factors remains unknown.       
 
2.4 Dietary Intake in Children with Cancer  
The challenges of conducting dietary studies among healthy and ill individuals have been well 
described (Freudenheim, 1993; Kushi, 1994).  Issues such as adherence to the methodology of 
dietary collection, loss to follow up, incomplete data collection, and the cost of large studies are 
frequently encountered and reduce the investigators ability to evaluate meaningful changes in 
diet over time.  The relatively low incidence of childhood cancer, (approximately 12,000 
children each year in the United States) makes data collection in a large homogenous patient 
group difficult.  Ideally, an understanding of caloric needs would be complemented with 
measures of basal metabolic rate and energy expenditure as these are the largest influences on 
dietary needs and have been found to be modified by a malignancy (Galati et al., 2011).  To date, 
no study has comprehensively evaluated dietary intake in combination with assessment of energy 
expenditure, nutrient utilization, and basal metabolic rate.  A review of the available data is 
described below and presented in Table 3.   
 
Dietary intake in 26 children (age range 5-16 years; male=16/female=10) with heterogeneous 
diagnoses was compared to 26 unmatched healthy controls (Bond et al., 1992).  Dietary intake 
was collected with a weighed food record and basal metabolic rate was evaluated one week 
before chemotherapy.  Energy intake was below the RDA in children with ALL, children with 
solid tumors, and healthy controls (Mean=1822 kcal per day (SEM=140); Mean=1877 kcal per 






differences in basal metabolic rate between cases and controls suggesting that dietary intake and 
energy expenditure is similar to that of healthy children.  A later study included measures of 
body composition, (weight, height, MAUC, TSF, and bioelectrical impedance assay (BIA)) 
along with dietary intake (24-hour recall for children with ALL; 7-day food record for controls) 
in 15 children (age range 2-16 years; gender-NR) with standard risk ALL and 15 age-matched 
controls.  Dietary data was collected at diagnosis, Day 22, Day 36, and Day 71 of treatment 
(Delbecque-Boussard et al., 1997).  Two of 15 patients were malnourished at diagnosis as 
defined by WFH a finding that contradicted studies performed by Reilly et al.  At each of the 
four timepoints, the caloric intake of children with ALL was 47%, 58%, 85%, and 85% of the 
French RDA, respectively (mean intakes not reported).  Total calorie intake in controls was 
104% of the French RDA.  For protein, children with ALL reported 1.7, 2.9, 2.5, and 2.7 times 
the RDA, which was less than controls (3.4 grams per day), although no P value was reported.   
Children with ALL had significantly lower respiratory quotient compared to controls at diagnosis 
(P<0.02) however this difference was not observed at Day 71.  This finding confirmed earlier   
work suggesting that disease status contributes to alterations in energy expenditure among 
individuals with cancer.  No significant differences in REE were observed between the two 
groups. Although caloric intake was below while intake of protein was above the French RDA in 
cases compared to controls, the difference in the methodology collecting dietary intake between 












































































RDA Children with ALL: 
83% of RDA 
(Mean=1822 kcal per 
day). 
 
Children with Solid 
Tumors:  89% of the 
RDA (Mean=1877 kcal 
per day). 
 
Controls: 87% of RDA 











Multiple Cases: FFQ 
 
Controls: FFQ 
NA Cases and controls 
reported similar calorie 
intakes.   
 
Children with cancer 
reported significantly 
higher intakes of 
potassium compared to 
controls. 
 
The control group 
reported significantly 
higher intakes of 
protein, zinc, 
phosphorous, 
riboflavin, and B12 
















ALL Cases:  24-hour 
recall  
 
Controls:  7-day 
food record  
French 
RDA 
Children with ALL: 
calorie intakes 47%-
85% of RDA. 
 









Cases:  19 (age 
2-15 y; 8M/11F 




Total calorie intake 
66% above the RNI. 
 
Protein > 100% of the 
RNI. 
List of Abbreviations: ALL-Acute Lymphoblastic Leukemia; FFQ- Food Frequency Questionnaire, 










Dietary intake and body composition was evaluated in 16 consecutive children (age range 2-15 
years; male=8/female=11) undergoing treatment for ALL (Halton et al., 1998).  Dietary intake 
was measured with a 3-day food record.  Total caloric intake was averaged for each of the 
collected timepoints, diagnosis and every 6 months of therapy (averaging about 5-7 food records 
per patient).  Dietary intakes were grouped as mean intakes by age.  Total calorie intake was 
above the Canadian Recommended Nutrient Intake (RNI)) in 70% of children.  In all but one 
child, protein intake was greater than 100% of the RNI.  Mean change in the ratio of lean mass to 
total body weight was reduced by 5% by six months of therapy.  Body fat increased from 
diagnosis to completion of therapy from a mean of 22% to 28%, respectively.  Statistical 
significance was not reported.          
 
In a small cross sectional study, dietary intake obtained with a FFQ in 16 (male=7/female=9) 
children between 6-15 years of age with varying cancers and at different stages of therapy were 
compared to 19 healthy controls matched by age and gender (Galati et al., 2011).  Energy 
expenditure was measured by indirect calorimetry, controlling for recent dietary intake with a 3-
hour recall. Body composition was measured with BIA. The authors found no significant 
difference in anthropometric measures (BMI, weight, height), body composition (lean body 
mass, fat mass), REE, or average respiratory quotient between cases and controls, a finding that 
was also reported in another study in 13 children (age range10-15 years; male=4/female=9) with 
solid tumors (den Broeder et al., 2001).  Dietary intake also revealed no significant differences in 
macronutrient intake.  Results obtained from a food frequency questionnaire revealed that 






(P=0.038), riboflavin (P=0.013), and B12 (P=0.00) and higher intakes of potassium (P=0.017) 
compared to controls.  Both groups did not meet the recommended number of servings for milk, 
cereal, and vegetables.  Children with cancer had increased intake of meat compared to 
recommended intakes.  Both groups met the recommendation for fruits servings.  Intakes 
exceeded the recommended portions for meat, sugar, and beans.   There were no significant 
differences between the groups.   
 
The studies reporting on changes in REE and energy expenditure suggest fluctuations occur over 
cancer care but the direction of change is not consistent and likely not directly related to either a 
decrease or increase in dietary intake.  Phases of therapy were not controlled for in most of the 
available studies, which attributes to the inconsistencies among studies.  An increase or decrease 
in dietary intake may be more reflective of the phase of therapy and disease status rather than the 
disease itself or may be related to reductions in daily function as most patients experience a 
decline in day-to-day activities when undergoing treatment for cancer.  Each of the small studies 
presented suggest that patients with cancer are either under or over the recommended dietary 
intakes and one study suggested that children were not adhering to recommended dietary 
patterns.  Protein intake appears to exceed recommendations.  The overall impact of less than 
optimal dietary intake remains largely unknown.  In each of the aforementioned studies, 
confounding variables such as diagnosis, phase of therapy, or class of anticancer drug were not 
controlled for in a systematic manner rendering the findings to scientific scrutiny.  The 
weaknesses of the available studies underscore the need for prospective studies exploring dietary 
intake in homogenous populations at systematic timepoints thereby improving the power to 






2.5 Nutrition status and Therapy-Related Side Effects and Overall Survival 
The overarching aim of understanding nutrition status among children with cancer is to identify 
timely nutrition interventions that can be designed and tested to minimize the progression and 
severity of malnutrition and the associated clinical outcomes.  Severe acute malnutrition is the 
cause of more than two million deaths worldwide (Talbert et al., 2012).  It has been well 
established that children who are malnourished experience impaired growth and development, 
reduced academic success, impaired physical function, and physical deformities (Black et al., 
2008).  Malnutrition is a risk factor for susceptibility to infections and remediation of 
malnutrition reduces the risk of developing an infection.  In a recent review exploring 31 
pediatric intensive care units centers in eight countries, optimizing nutrition therapy improves 
overall outcomes in children, including overall survival (Mehta et al., 2012).  Preliminary 
research suggests that benefits may also be realized for children with cancer if timely and 
effective interventions are designed, tested, and implemented into clinical practice.     
 
The effect of nutrition status on therapy-related side effects and survival has been investigated in 
multiple studies with varying scientific rigor.  The effect of TPN on tolerance to therapy 
(measured by therapy-related side effects) was evaluated in ten well-nourished patients (age 
range 2.5-12 years; gender-NR) with acute nonlymphocytic leukemia.  Children were randomly 
assigned to prophylactic TPN or standard oral nutrition during the induction phase of therapy 
(Hays et al., 1983).  Patients in the TPN group received significantly more calories (63.4 
cal/kg/day vs. 41.4 cal/kg/day) and protein (1.9 gm/kg/day vs. 1.1 gm/kg/day) compared to the 
control group. All patients in the TPN group experienced an increase in weight whereas only one 






between groups in arm muscle area or serum proteins were observed.  In the TPN group, patients 
were febrile for a mean of 20.5% days compared to 18.2% days in the control group.  Patients in 
the TPN group received antibiotics for a mean of 13.2 days (23.4%) compared to a mean of 36.8 
days (51%) in controls.  None of these differences were significant; a mere association between 
the provision of TPN and infection was suggested.  
 
In a slightly larger study these same relationships were not observed.  27 patients (age range 11-
33 years) with weight between 65-124% of pre-illness weight received TPN (n=12) or oral 
nutrition (n=15) (Shamberger et al., 1983).  Among the patients receiving TPN, total calorie 
intake was two times the control group and the protein intake was five times the control group 
demonstrating the effectiveness of TPN in augmenting oral dietary intake (methodology of 
measuring dietary intake was NR). However, no benefit on myelosupression, period of 
granulocytopenia (absolute neutrophil count) (<500mm3), thrombocytopenia, severe 
thrombocytopenia, or duration of thrombocytopenia were observed.  Transfusion requirements 
(less accurate measure of myelosupression) favored oral nutrition compared to TPN (P=0.05) 
bringing into question the benefit of TPN.  In this study, participants were generally free of bulk 
disease and well-nourished.  It is possible that different results may be observed in patients with 
established malnutrition who may have increased susceptibility to therapy-related side effects, 
especially infections.   
 
The final small study was a randomized study conducted in 27 well-nourished children (age 
range 2.5-17 years; gender-NR) receiving radiation to the abdomen.  Participants were 






(Ghavimi et al., 1982).  Nutrition status was indicated by height, weight, TSF, and MUAC.  
Patients in the TPN group gained significantly more weight than controls, 12.3% vs. 1.4% 
(P=0.006).  Four of the fourteen patients in the control group became malnourished and TPN 
was initiated.  MUAC was significantly different at the initiation of the study (P=0.002) and at 
the end of the study (P=0.018) however controls had higher TSF at initiation compared to the 
TPN group (P=0.018).  This difference was not apparent at the end of the study.  No differences 
in biochemical parameters, dietary intake, or anthropometric measures were observed after three 
months.  Dietary intake did not correlate with weight changes suggesting it may be unreliable.  
The methodology in the collection of dietary data was not reported.  The TPN group experienced 
an increase in therapy-related side effects as measured by reduced frequency of bowel 
movements (P=0.007), lower white blood cell count and hemoglobin (P=0.002), and increased 
number of days with fever (P<0.001).  The TPN group experienced fewer dose reductions 
(P=0.034) suggesting some benefit.  No difference in survival was observed between the two 
groups.  Consistent themes among these early studies are difficult to describe as the studies were 
limited, small, and heterogeneous.  It is possible that a ceiling effect may exist with the provision 
of TPN in that improved weight and reductions in therapy-related side effects may only benefit 
those patients who are malnourished as has been observed in other clinical conditions.   
 
Recent studies have acknowledged the weaknesses in the early nutrition literature and have 
begun to evaluate nutrition status in children with a homogenous diagnosis and larger sample 
sizes.  Lange et al. demonstrated a relationship between BMI percentile at diagnosis and survival 
in 768 children with acute myeloid leukemia (AML) (age range= 2-19 years; 






and 14.8% of patients were obese.  After controlling for age, race, leukocyte count, cytogenetics, 
and stem cell transplant, underweight patients (HR, 1.85; 95% CI, 1.19-2.87; P=0.06) were more 
likely to experience treatment-related mortality (HR, 2.66; 95% CI, 1.38-5.11; P=0.03) while 
obese patients experienced poor outcomes (HR, 1.88; 95% CI, 1.25-2.83; P=0.02) and increased 
treatment-related mortality (HR, 3.49; 95% CI, 1.99-6.10; P<0.001).  The hazard ratios observed 
in this study are not trivial.  The authors conclude that the observed reduction in survival is equal 
to the advances in the survival of AML over the past ten years. In a more recent study performed 
in 314 children with AML, patients with a healthy weight experienced a superior survival 
compared to patients who were under- or over-weight (P=0.01) Treatment-related mortality was 
also higher in patients under- or over-weight (P=0.009) (Inaba et al., 2012).  These studies 
underscore that although significant advances in overall survival have been achieved in children 
with cancer, addressing supportive care is crucial in order to sustain current achievements and 
further improve outcomes.   
 
Three smaller studies performed in children with solid tumors explored the effects of nutrition 
status on therapy-related side effects and survival.  One study incorporated measures of dietary 
intake into the study design.  In a retrospective review of 139 children (age range 9-18 years; 
male=77/female=62) with either Ewing’s or osteosarcoma, nutrition status (measured by BMI 
percentile) was collected at diagnosis and at six timepoints in therapy (diagnosis, 3, 6, 9, 12, and 
24 months) (Tenardi et al., 2011).  At baseline, 10.1% of patients were underweight, and 17.2% 
were overweight.  Weight significantly declined during therapy as measured by BMI Z-score (-
0.57 for weight and -0.73 for BMI Z-scores, P<0.001), reaching a nadir at 12-months.  Children 






compared to children with less than 108 hospital days.  No significant differences in survival 
were observed.   Hingorini et al. evaluated nutrition status in 498 children (age range 3.7-30 
yeras; male=274/female=224) with osteosarcoma at diagnosis and evaluated changes in BMI on 
therapy-related side effects (Hingorani et al., 2011).  At diagnosis, 73 patients (14.7%) had a low 
BMI, 382 patients (76.7%) had middle BMI, and 43 patients (8.6%) had a high BMI.  There was 
a trend towards wound infection and slough in patients with a low BMI (OR= 2.0; P=0.07).  
Finally, in 468 patients with rhabdomyosarcoma (age range=2-21 years; male=296/female=172), 
greater than ten percent weight loss at 24 weeks was associated with more therapy-related side 
effects and hospital days but not infection rate, failure free survival (interval between diagnosis 
and progression or death) or overall survival (interval between diagnosis and death) (Burke et al., 
2012).  Baseline obese patients (>95th percentile BMI) had inferior failure free survival but not 
overall survival while underweight patients (<5th percentile BMI) had borderline inferior failure 
free survival and overall survival compared with baseline average weight patients.  These 
differential findings of the effect of nutrition status on therapy-related side effects and survival in 
children with solid tumors compared to AML suggest that other medical conditions, type of 
anticancer therapy, or the natural progression of the disease may be influencing the observed 
effects of nutrition. Despite a better understanding is clearly needed, these studies do provide 
preliminary evidence that nutrition status may impact therapy-related side effects or overall 
survival in children with AML and solid tumors underscoring the importance of tailored and 
effective nutrition interventions and counseling for children with cancer.  
 
Three studies have explored the effect of nutrition status on survival and therapy-related side 






intensification (early vs. late), and age, BMI standard deviation score was not related to relapse 
(P=0.553) or outcome (P=0.720) in 1025 children with standard risk ALL (age range 0.2-14.9 
years; male=772/female=253) (Weir et al., 1998).  In contrast, Butturini et al. reported inferior 
survival in children and adolescents (n=4,260) who were obese at diagnosis, a finding that was 
especially prominent among children greater than or equal to ten years of age (Butturini et al., 
2007).  It should be noted that the latter study was performed in children with both low- and 
high-risk ALL, possibly explaining the differential findings reported in the initial study.  Most 
recently, a retrospective study exploring the effect of nutrition status at diagnosis and throughout 
therapy in children with high risk ALL found that those who remained malnourished for the 
majority of treatment experienced increased toxicity and reduced survival (Orgel et al., 2011).   
 
Taken together, these studies suggest that nutrition status may alter the risk of developing a 
therapy-related side effects but this is likely dependent on diagnosis and nutrition status at 
presentation.  Most recent studies suggest that sequential measurements of nutrition status may 
be necessary to understand the impact of poor nutrition on therapy-related side effects or 
outcome as the duration and severity of malnutrition or excess weight may be a better indicator 
of the effects rather than a single assessment at diagnosis.  It is likely that the effect of nutrition 
status is multifactorial and that increased vulnerability to therapy-related side effects may be 
dependent on pathological features of the tumor or the necessary cancer therapy as evidenced by 
differential findings in the studies exploring the effect of nutrition status in standard compared to 
high risk ALL.  Differences in tumor pathology alters the treatment schema and dosing which 
may necessitate the need for patients to be “nutritionally fit” in order to withstand the rigorous 






2.6.  Dietary Intake of Micronutrients and Therapy-Related Side Effects  
Few studies have evaluated the role of dietary intake of specific micronutrients and their 
relationship on therapy-related side effects.  Rather than consider the comprehensive effects of 
diet, most of the studies have explored the effect of dietary intake or supplementation with a 
single nutrient on the effect of a specified clinical condition.  Micronutrients of interest have 
been those associated with depletion as a result of cancer therapy (e.g. bone depletion and dietary 
intake of bone-metabolizing nutrients), antioxidants (micronutrients with antioxidant properties 
such as vitamin C, vitamin E, and selenium), and B vitamins.  
 
2.6.a Antioxidants 
Antioxidants are a class of micronutrients that exert antioxidant properties either through serving 
as cofactors in for enzymes (selenium, zinc) or by directly quenching free radicals (vitamin C, 
vitamin E).  Numerous studies have explored the effect of antioxidant status, measured by serum 
nutrient concentrations, in both adults and children with cancer.  A comprehensive review of 
these studies may be found elsewhere (Ladas et al., 2004).  Only one study has explored the 
effect of dietary intake of antioxidants on therapy-related side effects and survival in children 
with cancer.  The first prospective study was completed in 103 children with ALL (age range 
2.1-15.1 years; male=60/female=43) and collected dietary intake at three timepoints in therapy 
diagnosis, Day 28 of induction therapy, and 6-months after diagnosis.  The primary aim of this 
study was to explore the relationship of dietary intake, measured by a food frequency 
questionnaire and 24-hour recall, of antioxidants on therapy-related side effects in children 
undergoing treatment for ALL (Kennedy et al., 2004).  The authors found that children with 






hematologic side effect (P=0.04), greater intakes of vitamin C were associated with lower risk of 
hematologic or nonhematologic side effect (P=0.01), fewer delays in administration of scheduled 
chemotherapy (dietary intake: P=0.04), and fewer days spent in the hospital (dietary intake: 
P=0.04).  At diagnosis, those with higher vitamin A intakes (P=0.05) were more likely to have a 
slow response to treatment, whereas those with higher vitamin E intakes (P=0.05) were more 
likely to have a rapid response to treatment.  As this study was a small pilot in children with 
ALL, the study was exploratory in nature.  The authors concluded intakes were below 
recommendations and poor intake was associated with therapy-related side effects.  The authors 
suggest a larger study is needed to confirm the preliminary findings and explore intakes 
throughout the course of cancer therapy.  This was one of the first studies to also highlight the 
need for dietary counseling during cancer therapy so as to minimize the effects of identified 
nutrient deficiencies. 
 
2.6.b Bone-Metabolizing Nutrients 
Nutrients related to bone metabolism have been a target area of research due to the observation 
of increased incidence of bone fractures during and after treatment for ALL (Kaste et al., 2001). 
While the contribution of cancer therapy, the cancer itself, or lack of dietary intake results in 
children with ALL experiencing increased fractures is still undergoing scientific inquiry, studies 
have reported on the contribution of diet.  No study has investigated dietary intake of bone-
metabolizing nutrients during therapy, one study has reported in dietary intake among survivors 
of ALL (Tylavsky et al., 2010).  Children and adolescent survivors of ALL (n=164) reported on 
dietary intake with a food frequency questionnaire.  The authors reported on the percentage of 






magnesium, and fiber.  As well, the authors reported on the percentage of patients who met or 
exceeded the acceptable macronutrient distribution range (ADMR).  All patients were within the 
ADMR for protein, 36% for fat, and 92% for carbohydrate.  The authors explored mean intakes 
to the adequate intake (AI) for all bone-metabolizing micronutrients.  When evaluated by AI age 
group, the majority of survivors between the age of 9-13, 14-18, and 19-30 years of age did not 
meet the AI for vitamin D, 15%, 15%, and 34%.  For calcium, 17%, 16%, and 34% were below 
the AI for calcium.  While the prevalence of poor intake was below that expected, it should be 
acknowledged that vitamin D and calcium have undergone revision since the publication of this 
article and a significant increase in the daily recommendation for vitamin D has been set forth by 
the National Academy of Sciences (e.g. AI=200 IU compared to RDA= 600 IU vitamin D/day).  
With the increased risk of bone morbidities among children and adolescents with ALL, this study 
promotes the need for a comprehensive approach to cancer care in which the integration of 
dietary counseling are woven into standards of care.  Consideration for supplementation of bone-
metabolizing nutrients may be required for this group of patients in hopes of minimizing the 
long-term effects of cancer or cancer therapy.  
 
2.6.b B Vitamins  
A final area of focus in the nutrition literature is that of B vitamins and the role deficiencies or 
excesses may have on the efficacy of cancer therapy as well as therapy-related side effects.  
Within the class of B vitamins, folate has received the most attention due to the inclusion of anti-
folate medications used for the treatment of ALL. The importance of dietary folate consumption 
in patients receiving methotrexate (MTX) has been widely debated as the avoidance of folate and 






A heightened interest in this recommendation has emerged as a result of the FDA mandate, 
effective January 1998, that all grain products (enriched breads, flours, corn meals, rice, noodles, 
etc) be fortified with 400 mcg of folic acid.  A serving of these products will yield about 10% of 
Daily Value (about 40 mcg).  In a post-hoc analysis, dietary folate intake was explored among 
107 children with ALL (Ladas, 2003).  Fortification significantly increased the amount of folate 
in the subjects’ diets (P<0.0001). Mean daily intakes increased by 29.6% (345 µg compared to 
491 µg). Mean dietary folate values were compared among subjects who incurred therapy-related 
side effects (n=17) and compared to subjects who did not experience a side effect (n=61).  
Dietary folate did not have a significant effect on the incidence of side effects between the two 
groups (P<0.70).   Therapy-related side effects related to anti-folates such as gastrointestinal 
sores did not demonstrate a significance difference.  The influence of dietary intake of folate is 
likely dependent host genetics and red blood cell folate levels (Robien et al., 2003).       
 
The family of B-complex vitamins have also been investigated for the prevention of neuropathy, 
a common side effect of cancer therapy have been published. Deficiencies in B vitamins have 
been correlated with a compromised neurological status and an increased incidence of 
neuropathy in other clinical conditions, including diabetes and HIV (Abbas et al., 1997; Ang et 
al., 2008).  B vitamins are a prescribed treatment in adults with other neuropathic conditions, 
including diabetes, HIV-treatment related, and alcohol-induced neuropathy (Ang et al., 2008; 
Peters et al., 2006).  Inadequate intake of B vitamins is associated in neurological dysfunction 
and has been associated with the development of neuropathy in other clinical conditions 
(Beltramo et al., 2008; Gorson et al., 2006).  Case reports and clinical studies have found that 






use of vitamin B6 in a four year old with ALL with moderate-severe neuropathy (Ozyurek et al., 
2007).  Administration of B6 (150mg/m2/day, orally) with pyridostigmine (3 mg/kg/day) during 
the maintenance phase of therapy was associated with resolution of neuropathy, and allowed for 
optimal doses of chemotherapy to be administered. Randomized, controlled clinical studies have 
reported a beneficial effect of B vitamins for the prevention of neuropathy in other clinical 
settings with few adverse events (Youssef et al., 2008).  A recent Cochrane Review found that 
administration of B vitamins in the setting of neuropathy is encouraging, but not conclusive (Ang 
et al., 2008).  While supplementation has been an area of interest, there are no published reports 
exploring dietary intake of B vitamins during cancer therapy in children with ALL. Large, 
epidemiologic studies are needed to accomplish this goal.   
 
 
2.7 Dietary Recommendations for Children Undergoing Treatment for Cancer  
In children with cancer, nutrition intervention and education is primarily based upon the expert 
opinion of the physician, dietician, and nurse with efforts focused on the treatment of 
malnutrition and prevention of cachexia.  Little consideration is given to the broader scope of 
nutrition education, especially during cancer therapy (Ladas et al., 2005).  Optimizing cancer 
care includes placing emphasis on all aspects of supportive care interventions that include 
nutrition education.  This is especially important for the child with cancer as clinicians have the 
additional challenge of supporting growth and development while delivering the recommended 
doses of anticancer therapy.  Clinicians should be compelled to include this into the scope of 
cancer care however the paucity of data has prevented nutrition intervention and education from 







Presently, dietary guidelines for children during and after cancer therapy are generally centered 
on the prevention of cancer and are reflective of those guidelines set forth for healthy children 
(www.choosemyplate.gov) without a history of cancer or for survivors of adult malignancies 
(www.aicr.org or www.cancer.gov) (American Institute for Cancer Research, 2012; Chlebowski, 
2003) These guidelines include the importance of weight management, fruits and vegetables, 
whole grains, and lean protein however do not address potential nutrient deficiencies that may 
develop as a result of cancer therapy.  Moreover, the guidelines are not modified to reflect the 
increased risk of nutrition-related conditions such as heart disease, metabolic disease, or obesity 
that are widely prevalent among survivors of childhood cancer. In adults, adherence to a cancer 
prevention diet is estimated to reduce cancer mortality by 22% (Balter et al., 2012).  The 
existence of such a relationship in pediatrics is unknown.  A void in data has resulted in extreme 
variation in the nutrition management and education for children with cancer (Ladas et al., 
2005).  Often, nutrition management and education mirror the recommendations for healthy 
children, are extrapolated from guidelines developed for other pediatric conditions, or are 
adapted from the adult literature.  It is reasonable to hypothesize that nutrition intervention and 
education guidelines may require modification for children with cancer especially given the 
extensive duration of cytotoxic therapy and myriad of nutrition-related side effects that are 
frequently encountered by children.   
 
However before epidemiologic studies investigating the benefit of revised nutrition practice and 
education for children receiving cancer therapy can be undertaken, current guidelines require 
standardization and modification considering the unique nutrition needs of this vulnerable 






degree to which children deviate from Dietary Reference Intakes will serve as to guide in 
developing standardized guidelines. Understanding the degree at which intakes are below or 
exceed the DRIs will aid in the identification of priority areas and serve as a reference so that 
current guidelines are evidence-based rather than based on empirical data.  To undertake such a 
task, a comprehensive understanding of fluctuations in dietary intake over the course of cancer 
therapy must be understood.  To date, only one small study exploring diet quality has been 
conducted in a homogenous group children with cancer (Kennedy et al., 2004).   
 
The present study builds upon the existing science by exploring dietary intake among children 
and adolescents with ALL representing a large homogenous population of children with cancer.  
The data collected with allow for comparisons among patients withholding the variation of 
various cancer regimens, a variable that has limited previous studies.   The present study will 
evaluate fluctuations in dietary intake by exploring changes in both macronutrient and 
micronutrients as compared to healthy children as well as reference values set forth by the 
National Academy of Science.  The data collected from this study will help to close a gap in the 
scientific literature and begin to provide a foundation for the development of nutrition guidelines 












Chapter 3:  Methods 
This chapter will provide the reader with details of the study design, data collection methods, and 
statistical considerations for the current study.   
 
3.0 Study Overview  
This study is a cohort study describing changes in dietary intake over the course of a 
standardized cancer therapy protocol in children diagnosed with ALL.  Dietary intake was 
measured at three timepoints in therapy (Time 1- no therapy (diagnosis); Time 2- high dose 
therapy (referred to as the induction phase); Time 3-low dose therapy (referred to as the 
continuation phase)).  Dietary intake was measured at each of the timepoints with a food 
frequency questionnaire (FFQ) that was completed by the parent or patient.  Macronutrient and 
micronutrient values were then compared to: 1) Data from the National Health and Nutrition 
Examination Survey (NHANES)- representing normative data of dietary intake in children 
residing in the United States; (U. S.Department of Health Human Services, 2007) and 2) The 
Dietary Reference Intakes (DRIs) which are recommended nutrient intakes for individuals set 
forth by the National Academy of Sciences (Otten et al., 2006).  Children and adolescents are 
described as being below, meeting, or above the DRIs.  Dietary intakes in children with ALL are 
described and compared to NHANES data and the DRIs in an effort to identify and recommend 
priority areas for nutrition intervention that could potentially minimize therapy-related side 
effects and maximize survival.  
 







Study Objective 1:  To describe macronutrient and micronutrient dietary intakes at three different 
time points: Time 1 (diagnosis (no therapy)); Time 2 (end of induction (high dose therapy)); 
Time 3 (continuation (low dose therapy)) in children undergoing treatment for ALL. 
 
Study Objective 2:  To compare mean dietary intake of macronutrients and micronutrients at 
three different time points:  Time 1 (diagnosis (no therapy)); Time 2 (end of induction (high dose 
therapy)); Time 3 (continuation (low dose therapy)), in children undergoing treatment for ALL to 
dietary intakes of children reported in National Health and Nutrition Examination Survey 
(NHANES).  
 
Study Objective 3:  To describe the percentage of children undergoing treatment for ALL that are 
below, meet, or exceed the dietary recommended intakes (DRIs) for macronutrients and 
micronutrients  at three different timepoints in therapy: Time 1 (diagnosis (no therapy)); Time 2 
(end of induction (high dose therapy)); Time 3 (continuation (low dose therapy)).    
 
3.0.a Treatment Study  
All patients that were enrolled on a Dana Farber Cancer Institute (DFCI) treatment study for 
ALL were eligible for participation in the current study.  The association of the treatment study 











All children and adolescents participating in the current study are undergoing treatment for ALL 
and being treated on a therapeutic protocol that was developed by the DFCI ALL consortium.  
The DFCI ALL consortium is one of the largest research consortiums in North America with 
members from institutions located in the United States, Canada, and Puerto Rico.  Participation 
in the companion study was optional for the children and adolescents and did not require an 
additional consent process.  Participation in the companion study provided the data for the 
current study, no additional consent process was required.  Eleven institutions representing the 
United States, Canada, and Puerto Rico recruited participants to the treatment as well as 









The aim of the treatment study is to investigate the efficacy of a specific treatment regimen for 
ALL.  The treatment study consists of six different phases of therapy that are delivered over a 
two-year period and administer high- or low-dose chemotherapy (Chapter 2, Table 1).  Some 
phases of therapy are more intensive for those patients with ALL that are classified as high risk 
ALL.  Classification of high risk ALL is based upon features of the leukemia present at diagnosis 
(Stanulla et al., 2009).     
 
The first phase of therapy is referred to as the prophase and administers high dose steroids.  The 
second phase of therapy, referred to as the induction phase, delivers high dose chemotherapy and 
its purpose is to kill the leukemia cells and achieve remission.  The third phase of therapy is the 
consolidation phase of therapy and continues to deliver high dose chemotherapy to kill any 
remaining leukemia cells.  The final phase of therapy is the continuation phase of therapy in 






slightly different in its length and can be a minimum of 32 days (induction phase) to 15 months 
(continuation phase).   
 
3.0.b  Companion Study  
Several adjunct studies, also referred to as companion studies, are available for participation only 
to children enrolled on the treatment study.  Since all patients that participate in companion 
studies are treated on the same protocol, companion studies offer the benefit of having all 
patients receive the same cancer treatment.  Large samples are also easier to obtain when 
conducting companion studies.   The dietary information used for the current study was available 
to the investigator from a companion study that is investigating the associations between dietary 
intake and therapy-related side effects from cancer therapy in children with ALL.  In the 
companion study, FFQs were administered to patients at three timepoints in therapy.  The 
primary aims of the companion study are to investigate the relationship between dietary intake of 
select micronutrients and their relationship with therapy-related side effects.  Specifically, the 
companion study will investigate the following three relationships:  (1) the association between 
dietary folate intake, serum folate values, and methotrexate-related side effects (e.g. mouth 
sores); (2) the association between dietary intake of antioxidants and incidence of infections; and 
(3) The association between dietary intake of bone-related nutrients and incidence of bone 
fractures.   
 
3.0. c  Current Study  
The current study utilizes data obtained in the companion study and reports on change in dietary 






ALL. Information on dietary intake is collected at Time 1 (diagnosis), Time 2 (Day 32 of 
induction therapy), and Time 3 (15 months post-diagnosis (continuation therapy)).  These time 
points were selected to reflect varying levels of chemotherapy exposure; Time 1 (no exposure to 
therapy), Time 2 (exposure to high dose therapy (induction); and Time 3 (exposure to low dose 
chemotherapy (continuation)).  Time 1 reflects no exposure to chemotherapy as the survey 
reflects dietary intake for the month preceding the diagnosis of cancer. The schedule and timing 
of administration of dietary surveys are described in Table 5.  In the current study, intakes of 
children with ALL were compared with those of children, as reported in NHANES (U. 
S.Department of Health Human Services, 2007).  The study also examined the proportion of 
children below, meeting or exceeding the recommended values for dietary intake, based on the 
DRIs (Otten et al., 2006).   
 
 
3.1.  Subjects  
Children and adolescents between the ages of 1 and 18, with newly diagnosed ALL (n=799) 
were recruited to the study.  Eligible participants for the described study were children and 
adolescents receiving treatment for ALL as per the DFCI treatment study.  The treatment study 
was open to recruitment in May 2005 and closed to accrual in December of 2011.  Completion of 
all study datapoints is expected in the Spring of 2013.  Consent to the treatment study was 






consent to the companion study.   For the dietary study, participation at each timepoint was 
optional.  Participants or their parents could accept or decline participation in the dietary study 
and continue to receive treatment for ALL as per the treatment study.  Patients declining 
participation were documented as such and coded as missing data (refer to section 4.0, table 7).             
 
3.2 Study Measurements 
3.2.a   Demographics  
Demographic data was limited to those variables being collected as part of the treatment study.  
Information on demographics were provided by the participating institutions and collected from 
the medical chart.  The demographic variables provided were: type of ALL (low- risk or high-
risk), country of residence (table 4), date of birth, gender (male or female), and ethnicity (White; 
White, Hispanic; Other, Hispanic; Black; Black, Non-Hispanic; Black, African-American; 
Asian; American Indian/Alaska; Other).   
 
3.2.b   Dietary Intake 
Three dietary tools were administered during the study period, The Youth and Adolescent 
Questionnaire (Appendix A), The Harvard Food Service Questionnaire (Appendix B), and the 
medical nutrition support form (Appendix C).     
 
3.2.b.1 Dietary Intake:  Macronutrients and Micronutrients 
The Harvard Food Services Questionnaire (HSFFQ) for children ages 1-5 years and the Youth 
and Adolescent Food Frequency Questionnaire (YAFFQ) for children ages 6-18 years were 






3 (low dose therapy). In the current study, administration of the YAFFQ and HSFFQ requires 
children and adolescents or their parents to recall their average intake of foods over a specified 
period of time.  For the current study it was one month.  The nutrients of interest retrieved from 
the data output from the YAFFQ and HSFFQ were the following:  total calories, macronutrients 
(fat (grams), carbohydrate (grams), protein (grams)), antioxidant vitamins (vitamins C (mg), 
vitamin E (mg), zinc (mg), B vitamins (folate (mcg), pantothenic acid (mg), thiamin (mg), 
riboflavin (mg), vitamin B12 (mcg), vitamin B6 (mg), niacin (mg)) and bone-metabolizing 
vitamins (calcium (mg), vitamin D (IU), vitamin K (mcg)). The use of dietary supplements was 
self-reported and was added into the dietary intakes from both dietary surveys.         
 
For children and adolescents 6-18 years of age, the YAFFQ was administered.  The YAFFQ asks 
participants how often, on average, they consume each of the 131 foods listed (such as mixed 
vegetables, macaroni and cheese, and peanut butter sandwich). Food portion sizes are determined 
by comparison with national standard surveys; such as, Nationwide Food Consumption Survey 
Foods Commonly Eaten by Individuals (specifically for ages 9–18 years), and the 'natural' 
serving size of foods (e.g. bread slice, apple) (Pao et al., 1982).  Additional questions are asked 
about the frequency of snacks on school days and weekends, and the frequency of eating meals 
and snacks away from home. Respondents indicate use of dietary supplements in the form of 
multivitamins/minerals or single nutrients.  Administration of the dietary questionnaire requires 
about 10-15 minutes of the respondent’s time and was completed by the patient or parent.  The 







The HSFFQ was administered to children less than or equal to five years of age.  The HSFFQ 
contains 103 items, including 84 foods and 19 questions about food habits and supplements.  In 
addition to the questions about intake of specific foods, the HSFFQ also collects information on 
infant feeding habits such as the type and frequency of formula or milk.  The HSFFQ inquires 
about foods commonly eaten by small children and includes a range of questions on fruits, 
vegetables, simple and complex carbohydrates, dietary sources of protein, and sweets.  The 
HSFFQ is completed by parent or guardian.  Questions about food preparation, condiments, and 
the use of multivitamins are included in the dietary survey tool.  This survey was also available 
in English, Spanish, or French.       
 
Both the HSFFQ and YAFFQ have been tested for reliability and validity in children and 
adolescence (Blum et al., 1999; Rockett et al., 1997; Rockett et al., 1995).  The results revealed 
by both the YAFFQ and HSFFQ were similar to those in other studies reporting on the reliability 
and validity of food frequency surveys (Rimm et al., 1992; Suitor et al., 1989; Willett et al., 
1985).  
 
YAFFQ: Reliability and Validity 
The reliability of the YAFFQ has been established in 179 children between 9-18 years of age 
(44% M / 56% F) (Rockett et al., 1995).  Participants completed two YAFFQs one year apart.   
Pearson correlations were reported for selected nutrients that included total calories, protein, total 
fat, carbohydrate, fiber, and calcium. Correlation between the two surveys was .41 indicating 
moderate reliability (Kushi, 1994).  For total calories, the correlation was .49.  Correlations for 






dietary surveys (Kushi, 1994). However, age and ethnicity were not significantly related to 
reliability. 
 
This study also reported on the validity of the YAFFQ. The data obtained from the YAFFQ was 
compared to normative data reported by the Nationwide Food Consumption Survey (NFCS) and 
NHANES II.  When compared to NFCS, mean caloric intakes were within 25% of one another.  
When the data obtained from YAFFQ was compared to NHANES, mean intakes were within 
20% for males.  A slightly wider range in nutrient values was observed for females. Overall, 
these data suggest that validity of the survey is moderate but in line with previously reported 
tests (Kushi, 1994).   The results of these studies are presented below.  Pearson correlation 
coefficients for individual nutrient are presented in Table 6.   
 
A second study reported on the validity of the YAFFQ in 261 children age 9-18 years of age 
(47% M / 53% F) (Rockett et al., 1997).  The majority of the population was Caucasian (96%) 
with 4% representing African-American, Hispanic, Asian or other ethnicities.  Participants 
completed two YAFFQs over a one-year period and three 24-hour dietary recalls over the same 
time period.  Mean intakes from the three 24-hour recalls were compared to the mean intakes 
obtained from each of the two YAFFQs.  Energy-adjusted correlation coefficients for select 
nutrients are reported in Table 6.  Overall, Pearson correlations between the first YAFFQ and the 











Summary of Validation Studies for  
YAFFQ and HSFFQ 
 YAFFQ1a YAFFQ2b HSFFQc 
Overall 0.45 0.42 0.52 
Macronutrients    
Calories 0.37 .039 NR 
Protein (g) 0.37 0.38 0.43 
Carbohydrate (g) 0.40 0.41 0.52 
Fat (g) 0.49 0.48 0.62 
Fiber (g) 0.46 0.40 0.26 
Antioxidants    
Vitamin E (mg) 0.51 0.45 0.56 
Vitamin C (mg) 0.54 0.51 0.58 
Zinc 0.46 0.41 0.31 
B Vitamins    
Thiamin 0.51 0.40 0.57 
Riboflavin  0.56 0.47 0.56 
Niacin 0.47 0.39 0.55 
Folate 0.58 0.52 0.55 
Vitamin B12 0.39 0.45 0.58 
Vitamin B6 0.52 0.45 0.58 
Bone Nutrients    
Calcium  0.55 0.52 0.60  
a Comparison of YAFFQ1 to three 24 hour recall (Rocket, et al., 1997) 
                       b Comparison of YAFFQ2 to three 24 hour recall (Rocket, et al., 1997) 
                      c Comparison of two HSFFQ to three 24 hour recall (Blum, et al., 1999) 
 
 
recall was .42.  A slightly higher correlation was observed in males (.47) compared to females 
(.44).  While these correlations may be low, the correlations are still within acceptable ranges for 
dietary surveys.  Additionally, the reported correlations reflect those of other biological tests 
such as blood pressure and skinfold tests (Kushi, 1994).     
 
This study also compared mean values obtained from the YAFFQ to energy intakes observed 
from national surveys, NFCS and NHANES II.  Males reported slightly higher total caloric 






Younger children (9-13 years of age) tended to report higher intakes on the YAFFQ.  In contrast, 
older children (14-18 years of age) reported higher intakes on the 24-hour recalls.  Overall, the 
authors reported that energy intakes obtained from the YAFFQ were estimated to be 5-10% less 
for males and 12-21% higher for females compared to national surveys. The authors suggest that 
this is within acceptable ranges of other dietary surveys.         
 
HSFFQ: Validity  
The HSFFQ has been validated in 233 children between the ages of 1-5 and visiting a WIC clinic 
in North Dakota (Blum et al., 1999).  Fifty six percent of the population was Native American 
and 44% were Caucasian.  Correlations between the average intakes of the two HSFFQ and three 
24-hour recalls were reported. The average Pearson correlation coefficient for the entire cohort 
was 0.52 (table 6).  Nutrient correlations were variable and ranged from poor to moderate.  Poor 
correlations were observed for dietary fiber (0.26) whereas moderate to good correlations were 
observed for fat (0.62), vitamin E (0.56), vitamin C (0.58), and folate (0.60) along with a few 
other select nutrients (table 5).  Pearson correlations were also reported by ethnicity.  This 
analysis revealed similar correlations between ethnic groups, 0.49 among Caucasians and 0.51 
among Native-Americans suggesting moderate validity for a dietary tool (Subar et al., 2001).  
The HSFFQ has not been tested for reliability.         
 
3.2.b.2 Diet Intake:  Total Parenteral Nutrition (TPN) and Enteral Feeding  
The provision of medical nutrition therapy is often a consequence of anticancer therapy. For 
standardization of data collection, a medical nutrition therapy form (Appendix C) was developed 






oral nutrition supplements (e.g. Pediasure, Ensure, and Boost) and TPN at each of the designated 
timepoints.  Research assistants at each of the participating institutions completed the medical 
nutrition therapy form for each patient, regardless of whether received TPN or EN, at each of the 
three timepoints.  The medical nutrition therapy form provided information on the brand of 
nutrition formula and the prescribed dose (e.g. number of cans of supplement per day).  If enteral 
feeds were administered, the formula, rate, and duration were reported.  The nutrients delivered 
by the scheduled dose were then calculated by the nutritionist at Columbia University and 
manually added into the individual’s dietary analysis produced by the FFQ.  Due to institution 
limitations, the study was not able to collect detailed nutrient information on patients who 
received TPN.  Use of TPN was captured by institutions indicating its administration during the 
timepoint as ‘yes’ or ‘no’.  Medical nutrition therapy forms accompanied each FFQ.  Institutions 
were contacted if the data collection form for enteral nutrition was not received in order to limit 
missing data.         
 
3.2.c Reference Values for Dietary Intake  
Dietary intake obtained from FFQs was compared to two values, the Dietary References Intakes 
(Otten et al., 2006) and normative data from The National Health and Nutrition Examination 
Survey (U. S.Department of Health Human Services, 2007).   
 
3.2.c.1 National Health and Nutrition Examination Survey (NHANES) 
NHANES is a national survey that began in 1999 and currently collects dietary information 
annually.  NHANES provides information on the mean intakes of most dietary nutrients for 






of Health and Human Services (HHS) and the U.S. Department of Agriculture.  The Center for 
Disease Control, a division of HHS, is responsible for the sample design and data collection of 
the dietary survey and the USDA is responsible for the methodology employed in the collection 
of dietary data and the maintenance of the food and nutrient databases (U. S.Department of 
Health Human Services, 2007).  The survey examines a nationally representative sample of 
about 5,000 persons each year across the United States.  Dietary data is collected by an in-person 
interview or over the phone by two non-consecutive 24-hour recalls.  Interviewers conduct the 
surveys at a mobile exam center and rely upon the five-step USDA Automated Multiple-Pass 
Method used for collecting interviewer-administered 24-hour recalls.  Data are reported as mean 
intakes by gender, age group, and race (U.S.Department of Agriculture, 2010).  A summary of 
the normative data reported by NHANES (2005-2006) may be found in Appendix E.  In this 
report, data is not reported for children under the age of two.     
 
3.2.c.2 Dietary Reference Intakes (DRIs) 
Dietary intakes were compared to the DRIs.  The DRIs are recommendations designed to serve 
as a reference to guide health professionals in the assessment and planning for the dietary needs 
of individuals and groups. For total calories, the DRIs define the recommended energy intake as 
“the amounts of energy that need to be consumed by individuals to sustain stable body weights in 
the range desired for good health (BMI from 18.5 up to 25 kg/m2) while maintaining lifestyles 
that include adequate levels of physical activity to maintain social, cultural, and economic 
activity” (National Academy of Sciences et al., 2002).  Recommended calorie intakes have been 
developed by age and gender.  For the macronutrients, fat, protein and carbohydrate, the 






macronutrient distribution ranges as a percentage of total calories (National Academy of 
Sciences et al., 2002).    
For micronutrients, the DRIs consist of four categories: Estimated Average Requirement (EAR), 
the Recommended Dietary Allowance (RDA), the Adequate Intake (AI), and the Tolerable 
Upper Intake Level (UL).  The DRIs were designed to meet the needs of seemingly healthy 
individuals and are not meant to be applied to those with acute or chronic disease or for the 
repletion of nutrients in patients who are malnourished. It is not known if these values are 
applicable to individuals with a chronic condition however other reference values are not 
available for clinical practice.  The DRIs are based upon scientific research and clinical trials 
documenting safety or efficacy of a specified nutrient.  For nutrients without clinical trials to 
guide practice, an AI is developed and is largely based in empirical knowledge.  The DRIs are 
the most widely used reference guide to determine the adequacy of individual and group diets 
and provides a systematic framework in which dietary data, obtained in individuals or groups, 
may be compared.  Summary tables of the DRIs may be found in Appendix D.   
 
3.3 Data Collection Procedures  
For this study, a designated research assistant at each of the participating institutions 
administered the age-appropriate FFQ to study participants.  Administration of dietary surveys 
was given to patients during a routine clinic visit to the outpatient center.  For patients that were 
in the hospital at the time of the datapoint, the FFQ survey was administered while they were at 
the hospital. For each institution, the training of research assistants was provided by the 
nutritionist and co-investigator of the study (E.L.) at the lead institution of the diet study 






consortium group meetings.  Institutions were advised to administer the dietary survey to the 
parent or patient within three working days of the designated timepoint.  If the child or 
adolescent were not willing, interested, or too young to complete the survey, the parent or legal 
guardian would complete the survey instrument.  Surveys not completed within this timeframe 
were documented as missing data.  Research assistants were instructed to advise participants that 
responses should reflect the previous month’s dietary intake.  The information was disseminated 
to each of the research assistants and was also included in a brief cover letter delivered to the 
patient at the time of administration of the FFQ.         
 
Upon collection of dietary surveys, research assistants were advised to ensure that the FFQ was 
complete.  Blank questions were reviewed with the respondent.  Surveys were then batched by 
each institution and sent to Columbia University for preparation for data analysis at intervals 
convenient for the participating institution.    The lead institution notified institutions if surveys 
were incomplete or clarifications were needed.  Once completed, surveys were then processed by 
the research group at Columbia University, in accordance with the guidelines set forth by the 
Channing Laboratory at Harvard University.  The YAFFQs are bubble-coded surveys that were 
coded and copied and sent by parcel post to the Channing Laboratory at Harvard University for 
scanning and analysis.  The HSFFQ are written surveys in which respondents indicate food 
frequency with a check mark.  Completed surveys were entered into a DOS-based data system 
(provided by the Channing Laboratory) by the team at Columbia University. Surveys were then 







The investigative team followed a standardized protocol to reduce the possibility of processing 
error.  For the HSFFQ, input of the dietary data into the database system was vulnerable to 
improper data entry, which may lead to misclassification.  To minimize this risk, a research 
assistant, who was not involved with the collection of dietary data, reviewed all data.  If 
improper data entry was identified, the data system was corrected and reviewed a third time for 
accuracy of data input before proceeding to data analysis.   
 
3.4 Statistical Analysis     
 Dietary intakes at three different timepoints in therapy are included in the dietary analysis for the 
described study.  Mean intakes are reported adjusting for total caloric intake.   Adjusted nutrient 
intakes are reported for the described analysis despite controversy on the utility of reporting 
absolute or energy adjusted nutrient intakes (Block, 2001; Willett, 2001).  Studies have found 
that energy adjusted intakes correlate better with biological markers of a specified micronutrient 
(Willett, 2001).  Holding energy constant allows the investigator to observe changes in the 
composition of the diet, however small they may be on disease risk (Willett, 2001).   
 
Categorization of patients into DRI categories were based on absolute intakes in which patients 
were categorized as below, meeting, or exceeding the recommended nutrient intake as denoted 
by the DRI by gender and age (Appendix D).  For calories, reference values for dietary intakes 
were calculated for each age and gender category assuming a sedentary activity level for all three 
timepoints.  Caloric intake for each patient was classified into four groups:  (1) as below the 
recommended intake, (2) met (caloric intake that was at or within 10% of recommended intake), 
(3) exceed by 10-24% (caloric intakes that exceeded recommendations by 10-24%), and (4) 
exceed by 25% or more (caloric intakes that exceeded recommendations by 25% or more).  The 






investigator of the current study.  Categorization of the percent of calories for dietary intakes of 
fat, protein, and carbohydrates were classified as below, met, or above the AMDR for the 
specified nutrient.  
 
Micronutrient intakes were also classified as below, met, or above for each nutrient.  The RDA 
served as the reference point for each micronutrient.  For those micronutrients, pantothenic acid 
and vitamin K, in which an RDA was not set, the AI served as the reference value.  
Micronutrient intakes that were below the RDA were classified at below.  Micronutrient intakes 
that were at the RDA and below the upper intake level (UL) were classified as met.  
Micronutrient intakes that were at or above the UL were classified as exceeding the 
recommended intakes.  For micronutrients in which an upper limit was not set (thiamin, 
riboflavin, B12, vitamin K, and pantothenic acid), micronutrient intakes were classified only as 




The distribution of mean intakes was explored by age and by timepoint for normality by 
skewness and kurtosis before and after the removal of outliers.  Non-normality was defined if the 
skewness (or kurtosis) statistic were +/- 3 times its standard error.  Outliers were defined as cases 
that were more than three standard deviations away from the mean for age. Fifteen patients met 
this criterion for exclusion.  An additional three patients were removed from the analysis due to 
dietary intakes below 100 calories per day or exceeding 5000 calories per day.  Re-evaluation of 
skewness and kurtosis resulted in most age groups meeting the normality assumption.  However, 
the model used for the current analysis, the linear mixed-effects model, is robust against 







3.4.a Sample Size 
A total of 799 children were recruited to the treatment study and enrollment is now complete.  A 
total of 615 surveys at Time 1 and 556 for Time 2 was collected and analyzed.  Collection of 
dietary surveys for Time 3 is still ongoing as the observation for the final patient will occur in the 
Spring of 2013.  Complete dietary data will not be available for analysis until late Fall of 2013. 
As of June 2012, the point at which data collection for this analysis was closed, 417 surveys had 
been collected and analyzed for Time 3.  All analysis was performed in SPSS (version 18.0) 
(SPSS Inc. Released 2009, 2009).        
 
 3.4.b Analysis Plan  
Study Objective 1:  To describe macronutrient and micronutrient dietary intakes at three different 
time points (Time 1 (diagnosis-no therapy); Time 2 (end of induction-high dose therapy); Time 3 
(continuation-low dose therapy) in children undergoing treatment for acute lymphoblastic 
leukemia 
 
A linear mixed-effects model method was used for analysis of changes in dietary intake over the 
three study timepoints.  Diagnosis (Time 1) served as the base of which subsequent analysis were 
compared.  The linear mixed-effects model was performed due to: (1) datapoints are not 
exclusive of one another—the same subject was measured repeatedly, (2) linear mixed-effects 
model provides more flexibility in handling unequal variances and missing data, and (3) the 
models presented in this study required controlling for time varying covariates (mean intake of 
calories change at each timepoint and analysis was adjusted for calories for macronutrients and 






(predictors measured over time). In summary, mixed model analysis provides a general, flexible 
approach in these situations.        
 
Study Objective 2:  To compare mean dietary intake of macronutrients and micronutrients at 
three different time points, (Time 1 (diagnosis (no therapy)); Time 2 (end of induction (high dose 
therapy)); Time 3 (continuation (low dose therapy)), in children undergoing treatment for acute 
lymphoblastic leukemia to dietary intakes of children reported in National Health and Nutrition 
Examination Survey (NHANES).  
 
Descriptive statistics were used to explore differences between children with cancer and children 
as reported in the NHANES dataset.  The cohort was categorized by age groups as reported by 
NHANES.  Group mean intakes of the cohort were reported as a percentage below or above 
NHANES data.   
 
Study Objective 3:  To describe the percentage of children undergoing treatment for acute 
lymphoblastic leukemia that are below, meet, or exceed the dietary recommended intakes for 
macronutrients and micronutrients  at three different timepoints in therapy: Time 1 (diagnosis-no 
therapy); Time 2 (end of induction-high dose therapy); Time 3 (continuation-low dose therapy).    
 
Participants were classified as under, met, or exceed the DRI and the proportion of patients in 
each group by timepoint was statistically evaluated.  Three comparisons of the categorical data 
were performed: 1) Time 1 to Time 2, 2) Time 2 to Time 3, and 3) Time 1 to Time 3. The 






to compare the nutrient intake categories from one time point to another.  Dietary intake for the 
cohort was not normally distributed when intakes were evaluated by nutrient, age, and timepoint 
(refer to section on normality).  The Wilcoxon Signed-Ranks Test does not assume normality in 
the data therefore it can be used when this assumption has been violated and the use of the 
dependent t-test is inappropriate. P values used in Wilcoxon signed-rank test are adjusted 
according to the Bonferroni correction.  The Bonferroni correction reduces the chances of 
obtaining false-positive results (Type I errors) when multiple pair wise tests are performed on a 
single set of data. Instead using the P value of < .05 to determine statistical significance, P values 
< .017 (e.g. .05/3=.017) are used to assess statistical significance of the results of the Bonferroni-
adjusted Wilcoxon signed-rank test.  
 
3.4.c Statistical Considerations 
 
The data are unbalanced repeated measures data, meaning that dietary data was not available for 
each patient at each datapoint.  Of the 615 subjects, 358 subjects have dietary data at all three 
time points.  To control for this unbalanced design, a mixed linear model was used to conduct the 
analysis as this is a fairly robust model to control for this weakness in the study design.  
 
The analysis assumed the data was missing at random.  To support this assumption, both listwise 
and pairwise deletions were performed to confirm the direction of effects were consistent.  The 
listwise deletion resulted in the inclusion of only those subjects in which dietary data for all three 
timepoints was available for analysis.  After listwise deletion, dietary data on 358 participants 
was available for all three timepoints.  Analysis on these 358 participants did not differ 






that the data were missing at random.  Thus, the data was evaluated utilizing the larger sample 







Chapter 4: Results 
 
This chapter will present the results for the current study.  The chapter will highlight significant 
findings that are especially relevant to directing change in clinical practice and identifying future 
opportunities for research.   
 
4.0 Completed and Missing Data  
Dietary data was completed and analyzed for 623 (78%), 563 (70%), and 422 (53%) patients at 
Time 1, Time 2, and Time 3, respectively (table 7).   Dietary data collection for Time 3 is 
ongoing and is represented by the 20% of datapoints classified as pending.  The 53% represents 
those data collected up through June 2012 when data collection for this study was closed.  A 
small percent of patients (5-6%) declined participation at each timepoint.  Two percent of 
surveys at Time 1, 5% of surveys at Time 2, and 10% at Time 3 of surveys were not collected 
due to death or change in clinical condition resulting in removal from the treatment protocol.  
Administrative errors (Time 1, 12%; Time 2, 15%; Time 3, 12%) consisted of improper 
completion by respondent or institution, institution failed to administer, or patient did not 














      
                 
         a Represents the total surveys completed out of the 799 eligible patients;  b 8 surveys at Time 1,  
         7 surveys at Time 2, and 5 surveys at Time 3 were removed due to data meeting outlier 
         criteria; c Pending surveys are either in data cleaning, or patient has not reached the Time 3  




The demographics of the study participants are described in Table 8.  A slightly larger proportion 
of patients were males (56.4%) than females. The mean age at diagnosis was 6.6 years with the 
majority of patients Caucasian (67%) or Hispanic (18.7%).  The remaining ethnicities included: 
other (8.1%), Black/African-American (3.7%), Asian (2.1%), and American Indian/Alaska 
(.3%), representing a small proportion of patients.  The majority of patients were diagnosed with 
low risk ALL (58.6%). The demographics of this sample reflect the typical demographics of 
children and adolescents with ALL (Stanulla et al., 2009).  
  
Table 7. 
Dietary Surveys: Completed and Missing Data 
  Time 1 Time 2 Time 3 
  Frequency Percent Frequency Percent Frequency Percent 
Completed a 623 78% 563 70% 422 53% 
Analyzed b 615 77% 556 70% 417 52% 
Patient Declined 39 5% 50 6% 42 5% 
Medical  16 2% 41 5% 81 10% 
Administrative Error 92 12% 122 15% 97 12% 
Other 29 4% 23 3% 0 0% 
Pendingc 0 0% 0 0% 157 20% 
Outlier 8 1% 7 0.9% 5 0.6% 







Table 8. Demographics of Study at Time 1 
Total Sample      667*  
Age (Mean/SD)      6.6 years (SD 4.6) 
Age Range       1 to 17.9 years  
Gender N Percent 
Male 376 56% 
Female 291 44% 
Total 667 100% 
Race N Percent 
White 447 67% 
Hispanic 125 18.7% 
Other 54 8.1% 
Black 25 3.7% 
Asian 14 2.1% 
American Indian/Alaska 2 .3% 
Total 667 100% 
Risk Group N Percent 
Low Risk 391 58.6% 
High Risk 276 41.4% 
Total 667 100%  
       *Represents the number of unique patients in the current study resulting  
      from pair wise deletion.    
 
 
4.2 Nutrition Support 
Table 9 describes the proportion of patients that received either enteral feeding (oral or 
nasogastric) or total parental nutrition (TPN) at each of the timepoints.  At diagnosis (Time 1), 
few patients were receiving any form of nutrition support with only .3% of patients receiving 
TPN and 1.9% receiving enteral nutrition.  By Time 2, there is an increase in the number of 
patients receiving nutrition support with 6.8% receiving TPN and 11.5% receiving enteral 
nutrition, an expected finding due to the initiation of high-dose cancer therapy (table 1).  By 
Time 3, few patients received enteral nutrition (3.8%) while no patients received TPN.  The use 
of nutrition support was also reported by age group.  Administration of nutrition support was 
most frequent among the youngest patients.  At Time 2, 15.6% and 7.2% of patients 1-1.99 and 






more frequent among these age groups with 25% and 11.4% of patients, respectively, receiving 
enteral nutrition at Time 2.  By Time 3, TPN was not administered to any participant however 
the use of enteral nutrition was still administered to a small percentage of participants. 
     
 
Table 9. 
Percentage of Patients Receiving Nutrition Support by Timepoint 
Age Group Time 1 Time 2 Time 3 































                     














































































Table 10 compares the mean caloric intake across three timepoints by gender and age group. 
Overall, mean intake of total calories was significantly different between the three timepoints 
(P=0.003). When evaluated by age group, children 6-11 years of age reported significantly 
different mean caloric intake values between the three timepoints (P=0.000).  Among 
adolescents (12-19 years of age), mean caloric intakes were also different between the three 
timepoints (P=0.000), but only among males (P=0.002).  In general, calories are lower at Time 3 







Table 10 also presents mean caloric intakes reported by NHANES for children 2 years of age and 
older.  Contrary to expectations, dietary intake both early on in the disease process (Time 1) and 
during treatment (Time 2 and 3) appears to be similar to normative values as reported by 
NHANES.  Exceptions were for female children 6-11 years of age with higher intakes than 
normative values and 12-19 year old males with lower caloric intakes compared to normative 
values.  
 
Figure 2 presents the proportion of patients below, meeting, or exceeding the DRI for calories. 
The majority of patients exceeded the DRI for calories by age and gender while a smaller 







	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *Categorized by RDA by age, gender  
 
At Time 1, 6% of the population was meeting the DRI for calories whereas more than half of the 
patients (62%) exceeded the DRI by at least 25%.  Conversely, nearly 20% were below the DRI 
for total caloric intake at diagnosis. The percentage of patients above the DRI by at least 25% or 
more of caloric intake was reduced from 62% to 48% by Time 3, an unexpected finding.  This 
observation coincided with an increase in the proportion of patients under the DRI for calories by 
Time 1 to Time 3, 19% compared to 31%, respectively. There was a significant difference in the 
distribution of patients under, meeting, or exceeding the DRI for calories between Time 1 and 
Time 2 (P=0.016), Time 2 and Time 3 (P=0.000), and Time 1 and Time 3 (P=0.000).  Patients 
tended to be in a higher category (e.g. consuming more calories) at Time 1 compared to Time 2 
and 3 and Time 2 compared to Time 3.   
 
Comparison to the DRI was also analyzed by age group (table 11). The finding that the majority 
of patients exceeded the DRI by at least 25% was also apparent across all age groups and at each 
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timepoint (25 – 81%). Despite the use of nutrition support, 13-29% of patients between one to 
five years of age were below the DRI, an alarming finding as this represents the time at which 
growth velocity is at its peak. The study also found that 58% of males 12 – 19 years old at Time 













Overall, dietary intake of fat was not significantly different between timepoints (P=0.175) (table 
12).  When evaluated by age group, there were significant differences in fat intake between 
timepoints for males 1-1.99 (P=0.01), males 2-5 (P=0.01), and females 2-5 (P=0.003) years of 
age.   
 
Table 11.                                                                                                                   
Percentage of Patients Under, Meeting, or Exceeding                                                                       
DRI Calories by Age Group and Timepoint 
	  	   Under Met > 10%-24%   ≥ 25% 
Time 1 	  	   	  	   	  	   	  	  
1-1.99  13% 8% 10% 69% 
2-5 21% 6% 15% 57% 
6-11 6% 3% 10% 81% 
12-19 32% 9% 13% 46% 
Time 2 	   	   	   	  
1-1.99  28% 0% 16% 56% 
2-5 24% 7% 12% 58% 
6-11 14% 6% 7% 72% 
12-19 29% 9% 16% 45% 
Time 3 	   	   	   	  
1-1.99* - - - - 
2-5 29% 5% 17% 49% 
6-11 14% 10% 12% 63% 
12-19 58% 10% 7% 25% 









The mean intake of grams of fat by the cohort was compared to normative values reported by 
NHANES.  Dietary intake of fat was similar to normative values for all age groups except 
females 6-11 years and males 12-19 years of age.  Mean intakes of fat were above normative 
values at Time 2, compared to Time 1 and Time 3. An exception were males 12-19 years of age, 
dietary intake of fat was lower than normative values at all timepoints.  
 
Dietary intake of fat was also compared to the DRI (figure 3). The percentage of patients 
meeting the DRI decreased from Time 1 (70%) to Time 2 (63%) but returned to values observed 
at diagnosis by Time 3 (69%).  An increase in the percentage of patients that exceeded the DRI 






statistically significant.  Patients tended to be in a higher category at Time 2 compared to Time 1 
(P=0.000).  Patients tended to be in a higher category at Time 2 compared to Time 3 (P=0.000). 
 
 
        * Categorized by the AMDR  
 
The proportion of patients under, meeting, or exceeding the DRI for fat was further evaluated by 
by age group (table 13).  At each timepoint and age group, most patients were within the 
recommended values for fat.  However, dietary intake of fat above the DRI was most frequently 
reported at Time 2, with this most evident among older children compared to younger children.    
At the same time, nearly a third of patients particularly children less than two years of age were 
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Figure 3. 
Proportion of Patients Under, Meeting, or Exceeding DRI 
for Fat (% of Calories)* 



















4.3.c Protein  
Among the cohort, significant differences for dietary intake of protein were observed (P=0.003); 
however, this appears to be due to changes in dietary intake of protein in males (P=0.006) not 
females (P=0.144) (table 14). By age group, significant differences were only observed for 
children between the age of 2-5 years (P=0.000).  Although statistically significant, the 
differences at each timepoint reflected only one to three grams variations in daily protein intake, 




Percentage of Patients Under, Meeting, or 
Exceeding % of Calories from Fat by Age Group 
and Timepoint 
  Under Met Exceed 
Time 1 
   1-1.99  33% 64% 3% 
2-5 30% 66% 5% 
6-11 6% 79% 15% 
12-19 4% 75% 21% 
Time 2 
   1-1.99  35% 61% 3% 
2-5 17% 61% 22% 
6-11 3% 71% 26% 
12-19 4% 62% 34% 
Time 3 
   1-1.99* - - - 
2-5 27% 63% 10% 
6-11 11% 75% 13% 
12-19 8% 75% 18% 







In comparison to NHANES data, children and adolescents with ALL appear to consume more 
protein than normative data. This was most evident for children between 6-11 years of age in 
which mean intake of protein was consistently higher than normative values at each timepoint. 
Females, 12-19 years of age, were generally above (114-127%) whereas males 12-19 years of 
age were generally within normative values.   
 
Despite intake of protein being above normative values, the majority of patients (60-78%) met 
the DRI at each timepoint with a smaller percentage (21-39%) under the DRI (figure 4).   No 
intakes above the DRI were observed.  Dietary intake of protein appears to be consistent at Time 
1 and Time 2 but there is a significant differences in the distribution of patients under or meeting 
the DRI for all timepoints, Time 1 and Time 2 (P=0.03), Time 2 and Time 3 (P=0.00), and Time 












4.3.d Carbohydrate and Fiber  
Overall, intake of carbohydrates was significantly different between the three timepoints 
(P=0.027) (table 15). The differences between timepoints were only significantly different in 
children 2-5 years of age (P=0.000) in both females (P=0.000) and males (P=0.000).  Similar to 
dietary intake of protein, significant differences in the reported mean intakes of carbohydrate 
were small and probably not clinically meaningful.   
 
For most age groups, mean intake of grams of carbohydrates was near normative data based on 
NHANES.  The exception was females between 6-11 years of age who reported intakes 20-25% 
above normative values.   
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Mean intake of grams of carbohydrate was compared to the DRI for age and gender at each of 
the timepoints (figure 5).  The majority of children and adolescents met the DRI for carbohydrate 
(85-92%).  Significant differences in the distribution of patients who were under or met the DRI 
was observed between Time 1 and Time 3 (P=0.009), and Time 2 and Time 3 (P=0.003).  No 







	  	  	  	  	  	  	  	  	  	  	  	          * Categorized by the AMDR  
 
 
No significant differences in the intake of fiber (reported as grams of fiber) was observed for the 
cohort (P=0.082) (data not shown).  Mean intakes of fiber was one to three grams above 
normative data for each age group.  When fiber intake was evaluated by the percentage of 
patients meeting the DRI, most patients were not meeting recommended intakes for fiber.  At 
each timepoint, 91%, 93%, and 94% were below the DRI (data not shown).  No significant 
differences between timepoints were observed at any of the timepoints, Time 1 and Time 2 





4.4.a Antioxidants  
Mean intakes of vitamin C were significantly different between the timepoints for the cohort 
(P=0.004).  This was due to females (P=0.043), but not males (P=0.065) (table 16).  In general, 
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2-5 years of age, mean intakes at each of the timepoints were below (8-64% of reported values) 
normative values.  However, for older children and adolescents, mean intakes were above 
normative values (125-156%) at each timepoint.  When evaluated by the percentage of patients 
meeting the DRI (figure 6), patients tended to move from the met to the under category from 
Time 1 to Time 2 (P=0.000) and move back to the met category between Time 2 and Time 3 
(P=0.001).  There was not a significant difference in the distribution of patients by category 











* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL; Exceed= Intakes at or  
   above the UL 
 
Mean intakes of vitamin E remained stable over the three timepoints and did not vary 
significantly over time (P=0.195) (table 17).  Although significant differences were observed for 
some age groups and gender (table 16), no consistent themes appeared in the data. Similar to 
vitamin C, mean intakes were above those reported by NHANES at each of the study data points 
with this most evident in older children and adolescents (6-19 years of age).  Dietary intake of 
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Despite intakes being above normative values, the majority of patients, 74%, 68%, and 74% at 
Time 1, 2, and 3, respectively, did not meet the DRI for vitamin E (figure 6).  No patients 
exceeded the recommended values for vitamin E at any of the timepoints.  A significant 
difference in the distribution of patients under or meeting the DRI was observed between Time 1 
and Time 2 (P=0.014) represented by an increase in the percentage of patients meeting the DRI 
from Time 1 (26%) to Time 2 (36%).   No significant differences were observed between any of 
the other timepoints for vitamin E.       
 
For zinc, mean intakes were significantly different between timepoints (P=0.052) (table 18).  






younger males aged 1-1.99 and 2-5, P=0.007; P=0.045, respectively.  Mean intakes were also 
significantly different between timepoints for older females, 6-11 and 12-19 years of age, 
P=0.005; P=0.017, respectively.   For each group, mean intakes at each timepoint exceeded those 
values reported by NHANES.  Reported intakes in children with ALL were 10%-100% above 




High intakes of zinc were also reflected when the data was evaluated by the DRIs.  At timepoints 
1, 2, and 3, 46%, 39%, and 35% of patients exceeded the DRI for zinc, respectively (figure 6).  
More participants moved from a higher intake category to a lower intake category (e.g. moved 
from met/exceed to met/under) from Time 1 compared to Time 2 (P=0.000) and Time 1 to Time 






4.4.b B Vitamins  
The study evaluated changes in mean intake between the three timepoints in B vitamins that 
included analysis of folate, pantothenic acid, niacin, thiamin, riboflavin, vitamin B6, and vitamin 
B12, adjusting for total caloric intake.  Mean intakes are presented for the entire cohort and by 
age and gender.     
 
Fluctuations in the intake of folate are especially relevant for children with ALL due to the 
administration of anti-folate medications (methotrexate).  Significant differences between 
timepoints were only found for children less than 2 years of age (P<0.05) with this only evident 
in females (P<0.05), not males (P=0.603) (table 19).  When compared to normative data, mean 
reported intakes of folate were 11-22% below NHANES for younger children whereas older 







In comparison to the DRIs, 47%, 40%, and 38%, at each of the respective timepoints exceeded 
the recommended DRI for folate (figure 7).  
 
 
* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL; Exceed= Intakes at or  
   above the UL 
 
Participants tended to move from a higher to a lower DRI category from Time 1 to Time 2 
(P=0.000).  More patients were categorized in a higher DRI category at Time 1 compared to 
Time 3 (P=0.001).  No significant difference was observed between Time 2 and Time 3 
(P=0.828).    
 
For the entire cohort, no significant differences between timepoints were observed for any of the 
B vitamins including pantothenic acid, niacin, thiamin, riboflavin, B6, and B12 (refer to 
Appendix F). While some significant values were observed for select age groups and timepoints, 
there was not a consistent theme in terms of gender or group identified within the class of B 
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vitamins.   Mean intakes for males and females in all age groups were at or above those reported 
by NHANES.   
 
In comparison to the DRIs, adequate intake of B vitamins was also reflected in the proportion of 
patients meeting the DRI for each nutrient (figure 8).  As Figure 8 depicts, most patients were 
within the recommended DRI at each of the timepoints. Patients exceeded the recommended 
intake for niacin with 42%, 40%, and 45% of patients above the DRI at Time 1, Time 2, and 
Time 3, respectively.       
 
 
* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL; Exceed= Intakes at or  
   above the UL 
 
4.4.c Bone Metabolizing Nutrients 
For the cohort, mean adjusted intake of calcium was significantly different between timepoints 
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(P=0.285). When evaluated by age groups, significant differences were only observed for 
children 6-11 years of age (P=0.021), which was only evident for females (P=0.005), not males 
(P=0.650).  Comparison of mean intakes to normative data revealed children 2-5 years of age, 
reported mean intakes within 5% of normative values.  For children and adolescents between the 
age of 6-11 and 12-19, mean intakes were above those reported by NHANES with intakes 15-
51% higher than normative values.        
 
 
Comparison of intakes to the DRI for calcium revealed that the majority of patients did not meet 
the DRI for age and gender (figure 9).  The data revealed that 37%, 42%, 49% at Time 1, 2, and 








* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL; Exceed= Intakes at or  
   above the UL 
 
There was a significant difference in the categorization of patients between Time 1 and Time 3 
(P=0.000) and Time 2 and Time 3 (P=0.015).  No significant difference in the distribution of 
patients was observed between Time 1 and Time 2 (P=0.032).  A higher number of patients met 
the DRI for calcium at Time 2 compared to Time 3.  More patients met the DRI for calcium at 
Time 1 compared to Time 3.  Further analysis of calcium intake by age group revealed that 
deficiencies were observed at each group, with a higher percentage of adolescents 12-19 years of 
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* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL;  
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For the cohort, mean intakes of vitamin D did not significantly fluctuate between timepoints 
(P=0.664), reflecting stable intakes of vitamin D over the course of ALL therapy (table 21).  As 
observed with calcium, children between the age of 6-11 years of age reported significantly 
different mean intake between timepoints (P=0.004) however this was only significant for 
females (P=0.001), not males (P=0.254), an observation that was also found with mean intake of 
calcium.  Mean intakes at each timepoint exceeded normative values for most age groups.  
Dietary intake of vitamin D among children with ALL was nearly two times normative data for 
most age groups and timepoints.   
 
However, the majority of patients were below the DRI for vitamin D (92% at Time 1, 93% at 
Time 2, and 91% at Time 3) (figure 8).  No significant differences between any of the timepoints 






As was observed with intakes of calcium, the distribution of patients under or meeting the DRI 




* Under= Intakes below the RDA; Met= Intakes at the RDA but below the UL; Exceed=  
Intakes at or above the UL 
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Finally, mean intakes of vitamin K revealed no significant difference in dietary intakes for the 
entire cohort (P=0.311) (table 22).  Interestingly, females between 6-11 years of age reported 
significantly different mean intakes between the timepoints (P=0.011).  Mean intakes for each 
age group were near or above values reported by NHANES.  This was especially evident for 
children greater than or equal to 6 years of age.  Mean intake for this group were two to three 





Most patients met the DRI for vitamin K at each of the timepoints (figure 9).  There was only a 
significant difference in the distribution of patients between Time 1 and Time 2 (P=0.000).  








4.5 Summary of Results  
Table 23 provides and overview of the summary of results observed for both macronutrients and 
micronutrients.  For each nutrient category, the Table 23 highlights most important findings 
related to: 1) Mean nutrient intakes at each timepoint; 2) Nutrient comparison to normative data 
reported by NHANES, and 3) Nutrient comparisons of dietary intake to DRIs.  
Recommendations for future research and clinical implications of these findings will be 









































Summary of Findings	  
Nutrient Mean Intakes Comparison to NHANES Comparison to DRI 
Macronutrient    
Calories     For the cohort, significant  
difference between  
timepoints. 
 
Significant difference in  
children 6-11 yrs., and  
males 12-19 yrs.   
 
 
Time 1: Intakes higher (7-11%). 
 
Time 2: Intakes at or above  
(1-21%). 
 
Time 3: Intakes at or above  
(1-11%).  
 
Time 1, 2, and 3: Males, 12-19 
yrs., below at each timepoint  
(8-22%). 
  
At each timepoint: 60-70%  
exceed DRI.   
 
At each timepoint: 19-31%  
below the DRI. 
 
Percentage of patients below  
the DRI increased from Time 1 
to Time 3. 
 
Fat For the cohort, no 
significant differences 
between timepoints.  
 
Mean intakes were highest 
at Time 2. 
 
Mean intakes were similar 
at Time 1 and 3. 
Time 1, 2, and 3: Intakes at or 
near (4-10%).   
 
Time 1, 2, and 3: Males, 12- 
19 yrs., 11-14% below.   
 
  
Time 1 and 3: Similar  
distribution in intakes under, 
met, and exceed. 
 
Time 1, 2, 3: 13-20% below 
the DRI. 
 
Time 2: Higher percentage 
exceeding DRI (24%).    
Protein For the cohort, significant 
differences observed.   
 
Differences not considered 
clinically significant.  
 
 
Time 1, 2 and 3: Mean intakes 
for most age groups above, by at 
least 46%.   
 
Intakes above most apparent for 
children 6-9 yrs.   
 
Time 1, 2, and 3:  The 
majority of patients met the 
DRI, 61%, 60%, 78%, 
respectively. 
 
Time 1, 2, and 3: 38%, 39%, 
and 21%, respectively, were 
below the DRI. 
Carbohydrate For the cohort, significant 
differences observed.   
 
Differences not considered 
clinically significant.  
 
Time 1, 2, and 3:  Mean intakes 
were within 25% of normative 
values.    
 
 
Time 1, 2, and 3: The majority 
of patients met the DRI, 92%, 






Table 23.  Continued 
Nutrient Mean Intakes  Comparison to NHANES Comparison to DRI 
Vitamin C For the cohort, significant 
differences observed.  
Differences not considered 
clinically significant.  
 
 
Time 1, 2, and 3:  Intakes 
were below children 2-5 yrs. 
(8%-39%) 
 
Time 1, 2, and 3:  In older 
children, intakes were at or 
near 2 times above.    
Time 1, 2, and 3:  80-93% 
met the DRI.  
 
No patients exceeded the 
DRI.  Small percentage under 
the DRI.   
 
 
Vitamin E Some significant differences 
observed.  Differences were 




Time 1, 2, and 3:  In all age 
groups, mean intakes were 
above (109-200%).   
Time 1, 2, and 3:  Majority 
under the DRI, 74%, 68%, 
74%, respectively. 
 
No patients exceeded the 
DRI. 
Zinc  Some significant differences 
observed.  Differences were 




Time 1, 2, and 3:  For all age 
groups, intakes were above  
(110-200%). 
Time 1, 2, and 3: Most  
patients met the DRI, 47%, 
49%, and 52%, respectively. 
 
Time 1, 2, and 3: Large 
proportion exceed DRI, 46%, 
39% and 35%, respectively. 
Folate For most age groups, no 
significant differences were 
observed.  
 
Time 1, 2, and 3: Intakes 




Time 1, 2, and 3:  Large 
proportion met DRI, 44%, 
43%, and 46%, respectively.  
 
Time 1, 2, and 3: Large 
proportion exceeded DRI, 
47%, 40%, and 38%, 






B6, B12  
For most age groups, no 
significant differences were 
observed.  
 
Time 1, 2, and 3:  Intakes 
were within normative values 
for each nutrient.   
The majority of patients met 
the DRI for each B vitamin. 
 
Time 1, 2, and 3:  A large 
proportion exceeded the DRI, 
42%, 44%, and 45%, 
respectively.   
Calcium For the cohort, significant 
differences were observed.   
 
For most age groups, no 
significant differences were 
observed.  
 
Time 1, 2, and 3:  2-5 yrs, 
were near normative values.   
 
Time 1, 2, and 3: All other 
groups were above (107-
148%).  
 
Time 1, 2, and 3:  A large 
proportion were below DRI, 
37%, 42%, and 49%, 
respectively. 
 
Time 1, 2, and 3:  63%, 57%, 
51%, respectively, met the 
DRI.   
Vitamin D For the cohort, no significant 
differences were observed.   
 
Some age groups reported   
significant differences, no 
patterns were observed.  
Time 1, 2, and 3: For all age 
groups, intakes were at or 
above (up to 2 times) 
normative values.   
Time 1, 2, and 3:  A large 
proportion were below DRI, 
92%, 93%, and 91%, 
respectively. 
 
Vitamin K For the cohort, no significant 
differences were observed.   
 
Some age groups reported   
significant differences, no 
patterns were observed.  
Time 1, 2, and 3: For all age 
groups, intakes were at or 
above (up to 2-3 times) 
normative values.   
Time 1, 2, and 3:  A large 
proportion were below DRI 
32%, 46%, and 40%, 
respectively.  The remaining 








Chapter 5:  Discussion 
 
This chapter will present a summary and discussion of the results of this study.  Implications for 
clinical practice and priority areas for future research will be presented.     
 
5.0 Overall Summary 
This study is the first prospective dietary study performed in a large cohort of children and 
adolescents receiving a uniform treatment for ALL.  The study was successful in demonstrating 
the acceptability and feasibility of performing dietary assessments at systematic timepoints in 
therapy at multiple institutions. Response rates were reasonable and similar to other studies that 
assessed diet in cancer patients (Schatzkin et al., 2009).  
 
Findings from this study did not support the hypothesis that the majority of children and 
adolescents with ALL have total calorie intakes below the DRIs.  Contrary to expectations, we 
found that the majority of patients exceeded the DRI for total calories at all three time points.  
These findings suggest that, despite receiving anticancer therapy, most children and adolescents 
with ALL were still able to consume adequate calories.  
 
At the same time, there were a small proportion (19% to 31%) of patients who were below the 
DRI for total calories and this proportion increased over the course of therapy.  This was 
especially evident for males 12-19 years of age who went from 29% at Time 2 to 58% at Time 3 
below the DRI for calories.  Subsequent analysis revealed that the majority of these individuals 






the need for careful monitoring of dietary assessment throughout all phases of treatment for ALL 
as this subgroup of individuals may be at particularly high risk for malnutrition.  
 
Similar to calories, a small proportion of patients were below the DRI for fat and protein, 
although the majority of patients met the DRI for these macronutrients.  There was an interesting 
finding for fat such that nearly one-quarter of patients exceeded the DRI at Time 2 (high dose 
phase of therapy).  Although practitioners would not likely advise patients to decrease fat intake 
at this phase of treatment, this may be an opportunity for clinicians to educate families on 
healthy sources of dietary fat, particularly since children and adolescents with ALL are at 
increased risk for obesity and cardiovascular disease.   
 
For micronutrients, findings suggest that special attention is warranted for dietary intake of 
vitamin E, zinc, niacin, folate, calcium, vitamin D and vitamin K in patients with ALL.  Dietary 
intakes in excess of the DRI (i.e. intakes above the ULs) were noted for zinc and niacin in a large 
proportion of patients.  In contrast, dietary intakes were below the DRI for calcium, vitamin D, 
vitamin K and vitamin E in the majority of patients despite a significant proportion of the 
population exceeding the DRI for calories.   
 
For folate, it was unexpected that nearly half of children and adolescents with ALL exceeded the 
DRI at Time 1.  The percentage of patients exceeding the DRI decreased over time, which may 
reflect avoidance of folate-rich foods while on anti-folate medications.  This is a dietary 
counseling approach that is based upon individual clinical practice rather than standardized 






genetic polymorphisms in folate-metabolizing enzymes as these are significant factors in the 
bioavailability and metabolism of folate (Robien, 2005).  For all other B vitamins, no noteworthy 
observations were found.  
 
This is the first cohort study to compare dietary intakes in a large population of children and 
adolescents with ALL to normative values reported by NHANES. The hypothesis that dietary 
intakes in children undergoing treatment with ALL will be different than that of normative data 
due to receiving cancer therapy was not supported.  This study found that, in general, dietary 
intake of macronutrients and micronutrients in ALL patients were similar to normative values 
implying that cancer or its treatment does not alter dietary intake in children with ALL.  In many 
cases, mean reported intakes of micronutrients were above normative values.      
 
The finding that the majority of patients are consuming greater than 25% of the recommended 
calories for age yet deficiencies in key nutrients are still observed suggests that better effort must 
be placed on the nutrition management of children and adolescents with ALL.  These findings 
suggest potential priority areas for nutrition education and intervention.  The effect of these 
future interventions on the development of therapy-related side effects and survival will be 
essential to forming nutrition guidelines specific to children with ALL.  
 
5.1 Macronutrients 
The results of this study begin to provide an understanding of changes in macronutrient intakes 
among children and adolescents undergoing treatment for ALL.  To date, the ability of clinicians 






exploring the timing and degree of fluctuations in the diet throughout treatment for ALL.  This 
study has helped to close this gap in science.           
 
5.1.a Calories 
In this study, children and adolescents with ALL tended to be below or above the DRI for 
calories with a small percentage of patients within the recommended guidelines.  
This study found that a moderate percentage of patients are not meeting the DRI for calories, a 
finding that has been reported in previous studies (Bond et al., 1992; Delbecque-Boussard et al., 
1997).  These findings are important in that they suggest that a select group of children and 
adolescents with ALL may be at increased risk of malnutrition. Subsequent analysis of the 
current data set revealed that the children below the DRI for calories were least likely to receive 
enteral support. These findings imply that consistent dietary assessment throughout all phases of 
therapy is a necessary component of supportive care in order to minimize the risk of malnutrition 
especially as the duration of malnutrition is adversely linked to survival in children with ALL 
(Orgel et al., 2011).  Supplementation with advanced nutrition support such as enteral feeds 
should be considered for children and adolescents with persistent dietary intake below the DRI, 
especially in children with clinical confirmation of malnutrition.  
  
This study also found that caloric intake in the majority of patients exceeded the DRI at all 
timepoints, a finding that is supported by some studies (Halton et al., 1998; Reilly, 2001) but not 
others (Bond et al., 1992; Delbecque-Boussard et al., 1997).  Two important conclusions may be 
drawn from this finding.  The first is that children and adolescents with ALL are consuming 






intake was assumed to be within the recommended range at the initiation and during the early 
phases of treatment.  Increased caloric intake was assumed to occur over the course of therapy.  
These common assumptions by clinicians were supported by numerous studies describing 
increases in weight over the course of therapy combined with small studies reporting excess 
calorie intake during low dose phases of therapy.  Clinicians hypothesized that prolonged 
exposure to steroids may lead to dietary behaviors that are associated with excess calorie intake.  
This study refutes these assumptions.  The finding that caloric intake for most age groups is 
within 10% of normative data at all timepoints does not lend support that children with ALL are 
eating differently than ‘healthy’ children residing in the United States.  Additionally, children 
with ALL are consuming excess intakes at diagnosis, supporting the idea that this behavior (i.e. 
consumption of increased calories) is not learned over therapy.  Combined, this suggests that 
other factors are likely influencing dietary intake that may or may not be the cause of weight 
gain during therapy for ALL.   
 
The second conclusion that may be gleaned is that while the majority of patients exceeded the 
DRI for calories during therapy, the proportion decreases rather than increases over the course of 
therapy, a findings that did not confirm the hypothesis of the current study which was that 
dietary intake increases rather than decreases over therapy.  The reduction in the percentage of 
patients exceeding the DRI for calories from Time 1 to Time 3 may be related to reduced 
physical activity rather than the cancer therapy itself.  This may be especially relevant for older 
children who are often advised to avoid sports activity during cancer therapy.  Previous studies 
have reported an association between increased weight during therapy and reduced physical 






at Time 3 may be a response to the reduction in physical activity by eating less.  The well-
documented increase in children who are overweight or obese during therapy may be due to an 
insufficient reduction in total calories thus not adequately compensating for the reductions in 
physical activity during treatment.  Adolescent males may be especially vulnerable to 
fluctuations in physical activity due to the avoidance of organized sports during treatment for 
ALL.  Reduced activity that resulted in a reduction in caloric intake may explain the pronounced 
increase in adolescent males below the DRI for calories at Time 3.  It is also plausible that less 
attention to dietary intake is placed on adolescent males who may be less inclined to discuss 
nutrition-related issues with family members or clinicians.  A combination of factors is likely 
influencing the clinical picture.  Future studies may consider the inclusion of measurement of 
physical activity into the lifestyle assessment of children and adolescents with and survivors of 
ALL to gain a better understand of the interaction of these variables.      
 
5.1.b Fat   
This study was the first to explore fluctuations in dietary fat intake over the course of therapy in 
children with ALL.  A small percentage of patients at each timepoint were below the DRI for fat.  
In light of the increased risk of cardiovascular disease and obesity in this patient population, 
dietary counseling augmenting fat intake among these patients is not clinically indicated.  It is 
plausible that lower intakes of fat may benefit this population and serve to prevent subsequent 
weight gain.  Lower intakes of fat may also serve to prevent the development of nutrition-related 
side effects, such as hypertriglyceridemia, that may be fostered by excess intake of dietary fat.  
This study found that a small percentage of patients exceeded the DRI for fat.  An increase in the 






likely associated with high-dose steroids (Time 2).  This observation highlights a teachable 
moment for clinicians to counsel patients on healthy sources of dietary fat.  Dietary intake of fats 
that are high in unsaturated fat may be of benefit in relation to cardiovascular risk factors 
associated with treatment for ALL.  Dietary education during timepoints in therapy in which 
patients are at highest risk for nutrition-related conditions may be a cost effective intervention 
that may also empower families to take an active role in their child’s health during treatment.   
 
5.1.c Protein 
Previous studies have reported higher intakes of protein among children with cancer compared to 
recommended values (Delbecque-Boussard et al., 1997; Halton et al., 1998).  In the current 
study, patients did not exceed the DRI at any timepoint with the majority of patients within the 
DRI for protein. It can be concluded from this study, that most children and adolescents with 
ALL are within the DRI for protein for each of the timepoints.  Although intakes were above 
normative data, the data does not suggest a concern as no patient met the upper limit for protein 
at any of the evaluated timepoints.  The strengths of the current study design, in comparison to 
previously reported data, support the findings of the current study.           
 
This study also found that nearly 40% of patients are below the DRI for protein, a figure that has 
not been previously reported. This was observed during earlier phases of therapy compared to 
later phases.  Emphasizing diets high in protein or providing dietary counseling on strategies to 
increase intake of protein may be necessary early on in therapy, but not during later phases of 








This study found that the majority of patients met the DRI for carbohydrate and were near 
normative values.  This study did not explore the contribution of simple and complex 
carbohydrates or the glycemic index in the diets of children with ALL, areas that are open for 
future exploration.  Understanding these variables may provide a therapeutic opportunity for the 
management of medication-induced diabetes, a condition that is encountered by approximately 
15% of children with ALL during the first month of therapy (Koltin et al., 2012).  Among 
survivors of ALL, aberrations in glucose metabolism have also been described (Surapolchai et 
al., 2010).  In both of these clinical circumstances, the role of diet, especially variations in 
dietary intake of carbohydrates, is not known. Until more is understood, dietary counseling 
should reflect that of healthy children and emphasize a diet that is plentiful in complex 
carbohydrates from a variety of food sources.  
 
5.2 Micronutrients 
Three classes of micronutrients were investigated due to their potential association with therapy-
related side effects: antioxidants, B vitamins, and bone-metabolizing nutrients. 
 
5.2.a Antioxidants  
Mean intakes of vitamin C were similar to previously reported data in children with ALL 
(Kennedy et al., 2004) in that around 10% of children were found to be below the RDA for 
vitamin C.  This was a surprising finding as vitamin C is a common self-prescribed supplement 
during cancer therapy (Kelly et al., 2000).  This study did not provide evidence that children with 






that higher intakes of vitamin C were associated with reduced therapy-related side effects such as 
suppressed immune system. Subsequent analysis of the current data set will aim to confirm or 
refute these findings. If a benefit of higher intakes of vitamin C are observed, the implications for 
dietary counseling may be to consider educating families on foods rich in vitamin C as well as 
encourage the use of supplementation for a select group of patients.  However, until these data 
are available, dietary strategies focused on increasing intake of vitamin C for those patients 
below recommendations does not seem warranted.    
 
In contrast to vitamin C, the majority of patients were below the DRI for vitamin E.  This study 
found that the percentage of patients below the DRI for vitamin E is higher than previously 
reported.  The higher incidence in the current study is likely due to different reference values 
between the two studies (Kennedy et al., 2004).  The observation that mean intake of vitamin E 
were above normative data for each age group and timepoint suggests that this is not a 
consequence of treatment for ALL.  Although low intakes of vitamin E are lower than the DRI, 
they appear to be reflective of children and adolescents residing in the United States.  
 
Low dietary intake of vitamin E may be of particular concern as reduced intake may exacerbate 
side effects associated with cancer therapy.  For example, depleted levels of vitamin E have been 
associated with the development of neuropathy, a side effect often observed in children with 
ALL, especially among older patients (Weijl et al., 1998).  Supplementation of vitamin E appears 
to reduce the incidence of neuropathy (Argyriou et al., 2006).  Among children with ALL, 
greater intakes of vitamin E were associated with reduced infection (Kennedy et al., 2004).  The 






importance of dietary counseling emphasizing dietary sources of vitamin E such as wheat germ, 
nuts, broccoli, spinach, and tomato.  Supplementation may be indicated if dietary intake is not 
feasible.  Future studies should explore the efficacy of improved intakes on therapy-related side 
effects, particularly as they relate to vitamin E.      
 
Finally, dietary intake of zinc did not reflect that of vitamin C or vitamin E.  An unexpected 
finding of the study was that a large percentage of patients exceeded the DRI for zinc. The 
results of this study found that a smaller percentage of patients were below recommended values 
compared to previously reported data.  Sgarbieri et al. reported that 24% of Brazilian children 
undergoing treatment for ALL were below the RDA for zinc (Sgarbieri et al., 1999).  Whether 
this is representative of children residing in the United States is unknown. Dietary intakes above 
the DRI may be linked to higher intakes of protein as protein intake for the cohort was also 
consistently above normative values, a finding that was also observed for zinc.   
 
The ramifications, if any, of dietary intake of zinc that exceeds the DRI are unknown.  Previous 
studies have linked decreased serum zinc concentrations with the development of cancer (Alam 
et al., 2012; Chan et al., 1998) and reduced zinc levels have been associated with the malignant 
process, thus increased intakes may be compensatory (Gokhale et al., 2007).  This study did not 
collect biological markers of nutrients, thus it is unknown if elevated dietary intake of zinc 
manifested into elevated serum zinc levels.  This is an area that requires further investigation.       
 






This study is the first study to report on dietary intake of B-complex vitamins during treatment 
for ALL.  With the exception of folate, this investigation was exploratory.  For most B vitamins, 
the ramifications of dietary intakes below or above the RDA among children with cancer are 
unknown.  Supplementation with B vitamins has provided a clinical benefit in select groups of 
patients, particularly those at increased risk for neuropathy (Ang et al., 2008; Ozyurek et al., 
2007).  Whether supplementation is beneficial only in patients with low dietary intakes or 
deficiencies of B vitamins as evidenced by serum analysis remains unknown.  This study found 
that a small percentage of patients were below the RDA for select B vitamins.  A previous study 
performed in healthy children found that 0-10% of healthy children were below the estimated 
average requirement (EAR) for select B vitamins (Suitor et al., 2002).  While this study found 
that a higher percentage were below the RDA, the reference values between the two studies are 
not comparable.  
 
Investigation of folate is especially important within the context of ALL therapy as anti-folate 
drugs are an integral component of treatment.  Dietary intakes in excess of the RDA may be 
related to increased demand of folate due to the leukemic process. Conversely, patients may also 
be compensating for reduced folate status due to the methotrexate-containing regimen.  
However, the finding that children tended to be in a higher RDA category at Time 1 compared to 
Time 2 and 3 suggests that the administration of anti-folates does not precipitate increases in 
dietary intake.  Elevated intakes may mirror that of healthy children due to the fortification of the 
US food supply in 1998 as was also evidenced by mean intakes of the cohort were reflective of 
normative values.  This legislation has demonstrated success in improving blood folate levels 







The reduction in the percentage of patients that exceeded the RDA over time for folate may be 
related to dietary counseling advising patients to avoid folate-rich foods or folate-containing 
supplements during treatment.  The assumption that the increased intake of dietary folate will 
reduce the efficacy of anti-folate medications is a theoretical concern, despite preliminary 
evidence suggesting that supplemental intakes are safe among children with ALL (Ladas et al., 
2003).  Until a thorough assessment can be done of folate status that includes assessment of 
dietary intake, serum folate concentration, and polymorphisms in folate-metabolizing, it appears 
that it is prudent to continue to avoid supplementation with folate until evidence supporting or 
refuting high or low dietary intake of folate is obtained.  
 
5.2.c Bone Metabolizing Nutrients 
Bone morbidities are a significant therapy-related side effect in children and adolescents with 
ALL, with up to 21% of patients experiencing reduced bone density, a figure that exceeds the 
prevalence of 5% among healthy children (Kaste et al., 2001).  While previous studies have 
explored intake of bone-metabolizing nutrients after completion of therapy (Tylavsky et al., 
2010), this study is the first to report on dietary intake of bone-metabolizing nutrients during 
treatment for ALL.  This study provides the first line of evidence that dietary intake of bone-
metabolizing nutrients at diagnosis and during therapy are below the RDA for most children and 
adolescents with ALL.  
 
The percentage of patients below the RDA was higher among this cohort compared to previous 
report among survivors of ALL, likely due to increased attention to supplementation upon 






in line with other studies that have reported on dietary intake of vitamin D and calcium in young 
children (1-6 years of age).  Salvo, et al reported that 95% of Hispanic children and 97% of 
African-America were below the RDA for vitamin D and 31% and 38% were below the RDA for 
calcium, respectively (Salvo et al., 2012).  Dietary intake in that study was collected with a food 
record lending strong support for the data obtained from the current study.  In the current study, 
the observation that mean intake of bone-metabolizing nutrients were above those reported by 
NHANES at each timepoint may suggest that clinicians and parents are aware of the risk of bone 
depletion and that clinicians may be providing dietary counseling emphasizing increased intake 
of bone-metabolizing nutrients while parents may also be self-prescribing dietary 
supplementation of bone metabolizing nutrients.  
 
Dietary deficiencies in bone-metabolizing nutrients have significant research and clinical 
implications both during and after cancer therapy. First, these results endorse the support for 
proactive dietary counseling at diagnosis and during therapy.  Children and adolescents should 
be counseled on strategies to increase intake of vitamin D, calcium, and vitamin K.  
Supplementation of bone-metabolizing nutrients should be incorporated into the armamentarium 
of nutrition interventions, as diet alone may not be sufficient to compensate for low dietary 
intake.  When available, dietary interventions should incorporate biological markers of vitamin 
status such as vitamin D3 to ensure interventions ensure adequate dosing and effectiveness at 
improving biological markers of vitamin D. Special attention should be placed on adolescents, as 
bone accretion is most active in this age group.      
 






The current study classified dietary intake as below, met, or exceed the RDA by comparing mean 
intakes obtained from the FFQ to the RDA for age and gender. Another component of the DRI, 
the estimated average requirement (EAR), was designed to identify deficient intakes in 
populations and is the median distribution for population requirements (Kennedy et al., 2005).  
The EAR was developed to prevent nutrient-induced deficiencies rather than to prevent disease 
in populations.  The EAR is a minimum requirement for a group of similar individuals and is 
applied with the understanding that half the population will require dietary intakes above the 
established EAR (Yates, 2006).  In contrast, the RDA is designed to meet the needs of 97.5% of 
the healthy population.  On average, the RDA is about 20% higher than the EAR for each 
nutrient, two standard deviations above the EAR.  This figure is also not designed to meet 
populations who are at risk for nutrition-related morbidities but is set as the reference point for 
individual daily nutrient intakes and is the reference value used when performing individual 
dietary assessment.  
 
Controversy as to which reference value is best suited for the evaluation of populations has been 
previously described, yet neither address the best reference value for populations at increased 
risk for nutrition-related morbidities (Otten et al., 2006; Yates, 2006).  Children with ALL are at 
increased risk for many nutrition-related conditions such as heart disease, osteoporosis, and 
metabolic disorders.  The goal of this study was to highlight priority areas for potential 
intervention and thus maximize the proportion of patients at risk for deficiencies.  In performing 
the analysis in this manner, an overestimation of children and adolescents below the RDA 
(versus below the EAR) is likely to occur (refer to Appendix D).  A post-hoc analysis of the 






over the DRI as defined by the EAR.  While the percentage of patients under the DRI was 
tempered, dietary intakes below the DRI was still observed in the majority of children and 
adolescents.  For vitamin D, on average across timepoints, 50% of the population was below the 
EAR compared to slightly over 90% below the RDA for vitamin D.  Similar differences were 
observed for folate, calcium, and most antioxidants.  Evaluation of the reported dietary intakes 
by both the RDA and EAR resulted in similar conclusions however the application of the EAR 
lessens the magnitude of the need for proactive, systematic nutrition intervention. In developing 
both the RDA and EAR, neither value considers the unique risk factors attributed to children 
with ALL.  By using the EAR, the magnitude of children and adolescents that may benefit from 
proactive counseling is lessened while the risks for reduced quality of life and increased medical 
costs are elevated. With increased attention focused on individualized medicine, it seems 
reasonable to modify the reference point used for comparison among this cohort as they 
represent a unique population that is more aligned with the objectives of the RDA rather than the 
EAR.   
 
5.4 Strengths and Limitations  
 The study has several limitations.  In the current study, administration of the FFQ was 
administered due to the feasibility of its administration within a multi-site study.   The FFQ was 
designed to be self-administered, which was especially relevant for institutions without access to 
a trained dietitian or adequate research staff to administer the survey in-person.  However, the 
use of an FFQ may result in over-reporting of dietary nutrients.  In this study, over-reporting 
appears to be limited based upon a number of comparisons.  First, nutrient intakes obtained from 






diet information with the both a FFQ and 24-hour recall (Kennedy et al., 2004).  Second, for 
several nutrients, the observations were similar to other studies performed in children with 
cancer (Delbecque-Boussard et al., 1997; Halton et al., 1998; Kennedy et al., 2004).  In 
comparison to the current study, the three aforementioned studies collected dietary data with a 
24-hour recall, 3-day food record, and food frequency questionnaire combined with a 24-hour 
recall, respectively.  Third, a previous validation study for the YAFFQ found that males tended 
to report values under NHANES while females were more often above NHANES, an observation 
that was also observed in the current study (Rockett et al., 1997).  Finally, the percentage of 
patients below the RDA for vitamin D was within 1-3% of a study that compared intakes among 
healthy Hispanic or Africa-American school age children to the RDA (Salvo et al., 2012).  
Similar observations were found for calcium and vitamin E (Suitor et al., 2002).  Taken together, 
these comparisons lend support to the findings of this study and suggest that either over- or 
under-reporting was comparable to previously published studies.   
 
The study utilized the optimal tool for dietary analysis of a large cohort.  An FFQ was selected 
due to the reasonable cost and previous experience with the instrument on behalf of the 
investigative team.  A major limitation of this tool is that validation studies have not been 
performed in children with cancer.  A previous study utilized the same dietary tool and similar 
research methodology in children with ALL (Kennedy et al., 2004).  In that study, the YAFFQ 
was validated with a 24-hour recall and agreement was reported between the two survey 







In the current study, total calorie intake was evaluated by categorizing patients by age and 
gender.  The categorization of the results by age and gender allowed the investigator to control 
for confounding variables related to energy intake such as gender, age, height, lean mass, 
physical activity, and metabolic efficiency (Willett, 2001).  Due to limited personnel and 
financial support, the study was unable collect information on other lifestyle factors affecting 
dietary intake such as physical activity.  Comparison of mean intakes to the DRIs assumed a 
sedentary lifestyle for patients due to the medical recommendation of limited sports activity 
during cancer therapy.  The study was also unable to collect biological markers to correlate with 
dietary data. Collection of biological markers of nutrient intake would strengthen the results of 
future studies.  
 
The study was also limited by the lack of variability in all categories of nutrient intakes.  For 
example, the majority of participants exceeded the DRI for calories resulting in little 
representation of participants meeting or below the recommendations.  While this is an important 
finding for the study objectives of the current study, it reduces the power of the investigator to 
explore the effects of low and high dietary intake in subsequent analysis. Limited representation 
of patients below or exceeding the DRI must be considered in future analysis. 
 
This study was unable to collect information on all aspects of medical nutrition therapy, thus it is 
unknown if the provision of total parenteral nutrition would attenuate the significant 
relationships observed in this study.  At Time 2, the time at which the use of TPN was highest, 






expertise, it is unlikely that patients received TPN through the entire phase of therapy.  Analysis 
of the data removing these 38 patients did not attenuate the results for total calories.  
 
Finally, the current study required either the parent or child (>7 years of age) to complete the 
dietary survey.  Limitations in data collection prevented the investigative team to include 
respondent’s relationship to the patient.  For the majority of patients, a dedicated parent or legal 
guardian accompanies the patient however this was an assumption made on behalf of the 
investigator’s clinical experience.  This is a potential source of error however studies 
demonstrate parents are good surrogates for children’s dietary intake (Blum et al., 1999; Rockett 
et al., 1997; Rockett et al., 1995).  
 
There are several strengths of the current study.  Most importantly, the study minimized 
variability in dietary data by collecting information on diet at systematic points in therapy among 
a cohort of children with a single cancer diagnosis and treated on the same treatment regimen. 
This is a significant accomplishment as the majority of previous studies have been limited by 
each of the variables. This study administered a standard dietary tool at systematic timepoints in 
therapy while also collecting information on enteral nutrition.  This is the first study to 
accomplish a comprehensive dietary assessment during cancer therapy in children with ALL.     
 
Completion of the dietary assessment was also successful in this study.  Time 1 and Time 2 
represent complete datasets.  At each of these timepoints, 77% and 70% of surveys, respectively 
were completed and analyzed.  These figures are at (Johansson et al., 1997; Kuskowska-Wolk et 






Kuskowska-Wolk et al., 1992; Subar et al., 2001) previously published research.  It should be 
recognized that in the current study incentives, a frequent strategy implemented for completion 
of survey data, was not permitted in accordance with local institutional review boards.  Thus, 
respondents were provided the survey while in the hospital or during a routine outpatient visit.  
In each of the aforementioned studies, incentives were implemented to enhance survey 
completion. Parents or children refusing to participate constituted a small percentage of missing 
data.  For Time 3, 20% of surveys were in the data analysis phase or pending completion thus 
unable to be included in the current study.  The inclusion of these surveys has the potential for 
analyzed surveys at Time 3 to be as high as 72%, a figure in line with Time 1 and Time 2. Taken 
together, this study demonstrated that the exploration of diet during cancer therapy is feasible 
among children with cancer.  Additionally, the data suggests that parents and children are a 
motivated audience to participate in dietary studies and may be especially amenable to dietary 
counseling and intervention. 
 
Finally, this is the first study utilizing dietary intake to categorize the nutritional status of 
children and adolescents with ALL.  Previous studies have relied solely upon anthropometric 
indices to determine nutrition status despite the numerous limitations of these indices within the 
setting of cancer therapy, (Barr et al., 2011) which may result in misclassification (Barr et al., 
2011; Bliijdorp, 2012).  In Latin America, a region with a high prevalence of malnutrition, single 
assessments of nutrition status was less predictive of survival or therapy-related side effects, 
especially when relying on BMI alone (Sala et al., 2012).  The current study suggests that the 
addition of diet into the matrix of nutrition assessment may aid clinicians in identifying nutrient 






with ALL are at increased risk of many nutrition-related morbidities. While the immediate 
consequence of dietary intakes below the DRI may not be evident, the short- and long-term 
effect of persistently low intakes remains unknown. Clinical dietary practice may need to 
consider a more systematic approach in the nutrition assessment of children with cancer, until a 
better understanding of the effect dietary intakes below or above the DRIs are understood.  
 
5.5 Clinical Implications  
Changes in dietary intake and nutrition status are a hallmark of cancer therapy yet much of the 
literature describing fluctuations in diet is based on anecdotes and theory rather than evidence-
based science.  This study was successful in identifying seven priority areas of dietary 
assessment and counseling for children undergoing treatment for ALL (table 24).   These priority 
areas include: total calories, fat, protein, vitamin E, and bone-metabolizing nutrients (calcium, 
vitamin D, and vitamin K).  There is now clear evidence that routine dietary assessments should 
occur throughout the course of treatment for ALL.  Although interesting results were observed 
for other nutrients, specifically zinc, folate, and niacin, further information still seems needed 
prior to advising change in clinical practice.  
 
This study provides evidence that dietary assessment should be performed throughout treatment, 
even during low dose phases of therapy.  This suggests a significant change to the current 
standard of nutrition practice as routine nutrition assessments are not provided to children and 
adolescents with cancer (Ladas et al., 2005), but is in accordance with the multi-disciplinary 
approach that forms the backbone of the delivery of supportive care to children and adolescents 






uniform findings were not observed across all groups. Dietary assessment may include the use of 
anthropometric data for standard assessments combined with a modified 24-hour recall.  In 
children and adolescents in which poor dietary intake is suspected, a comprehensive 24-hour 
recall or food record may be clinically indicated.   Confirmation of poor dietary intake especially 
in the presence of clinically confirmed malnutrition should be remediated as per institutional 
standards of practice.  For those patients with excess calorie intakes, dietary counseling may 
emphasize strategies to minimize excess caloric intake, manage portion control, cravings and 
taste alterations, and adhere to a low-calorie diet if appropriate for age. 
 
The results of this study suggest there is an opportunity for clinicians to educate patients on 
dietary fat especially during the phase of therapy in which high-dose steroids are administered. 
Dietary education on healthy fats may be incorporated into the standard of care as modification 
of dietary fat has proven to be beneficial in the prevention of cardiovascular disease in other 
clinical settings.    
 
For protein, careful assessment of intake of dietary protein may be necessary early on in therapy 
for a select group of patients however this is not necessary for the majority of patients.  In 
patients that are suspected to be consuming low intake of protein, dietary assessments should 
include careful analysis of protein intake, ideally with either a food record or 24-hour recalls.  
For patients with persistently low intakes, counseling on increasing protein intake is warranted.  







For micronutrients, evidence now exists to develop clinical recommendations for vitamin E, 
vitamin D, calcium, and vitamin K.  Screening guidelines may be developed for vitamin E, 
vitamin D, calcium, and vitamin K to ascertain an individual’s risk of poor dietary intake of these 
nutrients.  When warranted, dietary supplementation may be considered to ensure intakes meet 
the minimum daily requirement. For vitamin D, serum assessment of vitamin D status may be 
woven into clinical practice to ensure adequate dosing and duration of supplementation with 
vitamin D.  Screening of serum vitamin D may accompany the systematic monitoring of bone 
morbidities, a practice that is slowly becoming integrating into the current standard of care for 












































Clinical Implications for Noteworthy Nutrients 
Nutrient Focus of Intervention  Timing of Intervention 
Dietary 
Assessment  
Ensure intake of macronutrients and 
micronutrients are not below or above 
recommended values.   
 
Dietary assessment needs to be tailored 
based upon age, gender, and dietary 
patterns 
At diagnosis and at systematic 
timepoints during all phases of therapy.   
Calories Dietary counseling should emphasize 
portion control and healthy food choices in 
the majority of patients.  
  
For patients that are below recommended 
guidelines, consider nutrition support to 
maximize caloric intake.   
Diagnosis-Initial consultation and 
assessment of nutrition intake.   
 
Patients with caloric intake below or 
above recommended values should 
continue to be monitored in a systematic 
manner during all phases of therapy.   
Fat During induction therapy (Time 2), dietary 
counseling may emphasize sources of 
healthy fats such as foods high in 
unsaturated fatty acids (fish, avocado, nuts, 
seeds).     
Diagnosis through first month of 
therapy (Induction phase) 
Protein Emphasize protein-rich sources only for 
children at risk for insufficient protein 
intake.   
At diagnosis and at systematic 
timepoints in throughout therapy.   
Vitamin E Emphasize foods rich in vitamin E. Foods 
high in vitamin E include nuts, seeds, kiwi, 
mango, and tomatoes.   Consider 
supplementation, if dietary intake does not 
meet the RDA.   
Routine assessments through all phases 
of therapy.  
Calcium Emphasize foods rich in calcium such as 
dairy and leafy greens.  Consider 
supplementation, if dietary intake does not 
meet the RDA. 
Routine assessments through all phases 
of therapy. 
Vitamin D Emphasize foods rich in vitamin D such as 
fortified diary products.   Consider 
supplementation, if dietary intake does not 
meet the RDA. 
 
Evaluation of serum vitamin D status may 
be considered to direct dosing 
recommendations. 
Routine assessments through all phases 
of therapy.  
Vitamin K Emphasize foods rich in vitamin K.  
Consider supplementation, if warranted. 







5. 6 Future Directions 
The results of this study have identified a variety of priority areas for future research.  As a first 
step, it will be important to confirm and expand upon the findings of this interim analysis once 
complete data is available for Time 3.  The final analysis should explore if the described 
relationships remain with the larger data set as well as perform advanced statistical modeling to 
identify trends over time.  For the highlighted micronutrients, subsequent analysis on the 
complete dataset may consider a thorough evaluation of folate to include genetic polymorphisms 
of folate-metabolizing genes and biological markers of folate intake. Additional micronutrient 
analysis may also explore the risks associated with excess intakes of niacin and zinc especially at 
it relates to therapy-related side effects and survival.  The influence of ethnicity, weight, and 
geographic location on the observed associations may also be explored, as these variables are 
influential in assessing dietary intake.  When possible, the inclusion of socioeconomic status may 
also provide a comprehensive understanding to nutrition status as this has been linked to reduced 
outcomes among children with cancer (Lightfoot et al., 2012).   
 
Secondly, the role of dietary patterns on therapy-related side effects during and after completion 
of therapy is an area for further exploration.  For example, while significant associations were 
not identified for carbohydrates, exploration into the quality of carbohydrates (simple versus 
complex), especially as intake relates to the glycemic index, may reveal interesting findings that 
are clinically significant.  Future studies may also consider exploring dietary patterns that include 
the ratio of saturated and unsaturated fat, servings of fruits and vegetables, and dietary exposure 
to phytonutrients. The understanding of dietary patterns during therapy may aid clinicians in 






children and adolescents may be more amenable to dietary intervention once treatment is 
complete.  This is a time when the focus is turned towards the prevention of late-effects and 
second malignancies rather than the day-to-day fluctuations that are often encountered during 
treatment for cancer.  
 
Future investigations need to give consideration to the complexity of dietary intervention during 
cancer therapy.  Dietary interventions targeting children and adolescents with ALL must be 
designed to be flexible and cognoscente of the side effects that may limit dietary intake such as 
changes in the taste and desire for food, “fussy eating”, and the psychosocial impacts of the 
diagnosis of cancer (Fleming, 2012; Pizzo, 2011).  Each of these factors may limit adherence to 
any dietary recommendation.  Tailored nutrition interventions will likely be required, as food 
preferences may need to be considered within the findings of dietary assessment.  The timing of 
dietary education and format of intervention is also a fertile area for investigation among 
children with cancer.  For example, distal lifestyle intervention programs are effective at 
modifying changes in dietary patterns and physical activity among adult survivors of cancer 
(Mosher et al., 2012).  With the increased use of technology among adolescents and young 
adults, this may be an ideal format to deliver nutrition education both during and after therapy.  
 
Future studies may also consider the investigation of the optimal tool for evaluating diet among 
children with cancer.  The strengths and weaknesses of the available dietary tools should be 
explored in this setting.  The utilization of electronic food records or recalls may ease the burden 
of data collection for investigators and increase opportunities for subsequent dietary studies in 






among children with cancer may also be considered.  The development of a systematic process 
for the implementation and training of the research and investigative staff will improve the 
reliability and validity and minimize incomplete data sets in future epidemiologic studies 
performed in children with cancer.      
 
Finally, this study may serve as a benchmark to direct the formation of dietary goals for children 
and adolescents with ALL.  As well, the reported mean intakes may serve as a reference point for 
future dietary studies in children with ALL.  Whether these results apply children with cancer 
diagnosed with malignancies outside of ALL remains unknown.   The current study design may 
also serve as a blueprint for exploration of diet in children with other types of malignancies in 
which malnutrition is thought to be a significant concern due to the nature of anticancer therapy.  
Future studies should explore this data in children at high risk for malnutrition that include 
children and adolescents with a brain tumor, undergoing stem cell transplant, or with a solid 
tumor.  The benefit of these scientific efforts will hopefully be more children and adolescents 
entering survivorship, which is the ultimate goal of medical professionals working in pediatric 
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• Use a NO. 2 PENCIL only.
• Do not use ink or ballpoint pen.
• Darken in the circle completely.
• Erase cleanly any marks you wish to change.
















YesNo If yes) a) How many
vitamin pills do















8. Where do you usually eat breakfast?
At home
At school
Don’t eat breakfast 
Other
7. Which cold breakfast cereal do you
usually eat?
Never eat cold breakfast cereal
6
7
6. How many teaspoons of sugar do
you ADD to your beverages or food
each day?
9. How many times each week (including
weekdays and weekends) do you usually eat
breakfast prepared away from home?
Never or almost never
1 - 2 times per week
3 - 4 times per week






None/less than 1 teaspoon per day
1 - 2 teaspoons per day
3 - 4 teaspoons per day





























































































Questionnaire refers to what you ate over the past year.








11. How many times each week do you usually
eat after-school snacks or foods prepared
away from home?
Never or almost never
1 - 2 times per week
3 - 4 times per week
5 or more times per week
10. How many times each week (including
weekdays and weekends) do you usually eat
lunch prepared away from home?
Never or almost never
1 - 2 times per week
3 - 4 times per week
5 or more times per week
10
11
13. How many times per week do you prepare
dinner for yourself (and/or others in your
house)?
Never or almost never
Less than once per week
1 - 2 times per week
3 - 4 times per week
5 or more times per week
12. How many times each week (weekdays and
weekends) do you usually eat dinner
prepared away from home?
Never or almost never
1 - 2 times per week
3 - 4 times per week
5 or more times per week
12
13
15. How many times each week (including
weekdays and weekends) do you eat late
night snacks prepared away from home?
Never/less than once per month
1 - 2 times per week
3 - 4 times per week
5 or more times per week
14. How often do you have dinner that is ready
made, like frozen dinners, Spaghetti-O’s,
microwave meals, etc.
Never/less than once per month
1 - 2 times per week
3 - 4 times per week
5 or more times per week
14
15
17. How often do you eat fried food away from
home (like french fries, chicken nuggets)?
Never/less than once per week
1 - 3 times per week
4 - 6 times per week
Daily
16. How often do you eat food that is fried at
home, like fried chicken?
Never/less than once per week 
1 - 3 times per week





How often do you eat the following foods:
Example If you drink one can of diet soda 2 - 3




(1 can or glass)
Never
1 - 3 cans per month
1 can per week
2 - 6 cans per week
1 can per day
2 or more cans per day







18. Diet soda (1 can or glass)
Never/less than 1 per month
1 - 3 cans per month
1 can per week
2 - 6 cans per week
1 can per day
2 or more cans per day
FILL OUT ONE BUBBLE FOR EACH FOOD ITEM
25. Wine or wine coolers
(1 glass)
24. Beer (1 glass,
bottle or can)
Never/less than 1 per month
1 - 3 cans per month
1 can per week
2 or more cans per week
24
25
26. Liquor, like vodka or rum
(1 drink or shot)
Never/less than 1 per month 
1 - 3 glasses per month
1 glass per week
2 or more glasses per week
Never/less than 1 per month 
1 - 3 drinks per month
1 drink per week
2 or more drinks per week
26
Example  If you eat:
3  pats of margarine on toast
1 - 2  pats of margarine on sandwich
1  pat of margarine on vegetables
5 - 6  pats total all day 
      then answer this way  
E2. Margarine (1 pat) - not
butter
Never
1 - 3 pats per month
1 pat per week
2 - 6 pats per week
1 pat per day
2 - 4 pats per day
5 or more pats per day
DAIRY PRODUCTS
28. Milk (glass or with cereal)
Never/less than 1 per month
1 glass per week or less
2 - 6 glasses per week
1 glass per day
2 - 3 glasses per day
4+ glasses per day
27
28
29. Chocolate milk (glass)
Never/less than 1 per month
1 - 3 glasses per month
1 glass per week
2 - 6 glasses per week
1 - 2 glasses per day
3 or more glasses per day
29
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19. Soda - not diet 
(1 can or glass)
Never/less than 1 per month
1 - 3 cans per month
1 can per week
2 - 6 cans per week
1 can per day
2 or more cans per day
18
19
20. Hawaiian Punch, lemonade,
Koolaid or other non-carbonated
fruit drink (1 glass)
Never/less than 1 per month
1 - 3 glasses per month
1 glass per week
2 - 4 glasses per week
5 - 6 glasses per week
1 glass per day
2 or more glasses per day
20
22. Tea (1 cup)21. Iced Tea - sweetened 
(1 glass, can or bottle)
Never/less than 1 per month
1 - 3 glasses per month
1 - 4 glasses per week
5 - 6 glasses per week
1 or more glasses per day
21
22
23. Coffee - not decaf. (1 cup)
Never/less than 1 per month
1 - 3 cups per month
1 - 2 cups per week
3 - 6 cups per week
1 or more cups per day
Never/less than 1 per month
1 - 3 cups per month
1 - 2 cups per week
3 - 6 cups per week
1 or more cups per day 23
SERIAL #







30. Instant Breakfast Drink
(1 packet)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
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32. Yogurt (1 cup) - Not frozen31. Whipped cream
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
30
31
33. Cottage or ricotta cheese
Never/less than 1 per month 
1 - 3 cups per month
1 cup per week
2 - 6 cups per week
1 cup per day
2 or more cups per day
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
32
35. Cream cheese34. Cheese (1 slice)
Never/less than 1 per month
1 - 3 slices per month
1 slice per week
2 - 6 slices per week
1 slice per day
2 or more slices per day
33
34
Never/less than 1 per month 
1 - 3 times per month
Once per week
2 or more times per week
38. Margarine (1 pat) - NOT butter
Never/less than 1 per month
1 - 3 pats per month
1 pat per week
2 - 6 pats per week
1 pat per day
2 - 4 pats per day
5 or more pats per day
35
37. Butter (1 pat) -
NOT margarine
Never/less than 1 per month
1 - 3 pats per month
1 pat per week
2 - 6 pats per week
1 pat per day
2 - 4 pats per day
5 or more pats per day
36
37
36. What TYPE of yogurt,
cottage cheese & dairy







39. What FORM and BRAND of






40. What TYPE of oil does










41. Cheeseburger (1) 42. Hamburger (1)
Never/less than 1 per month
1 - 3 per month
One per week
2 - 4 per week
5 or more per week
41
42
43. Pizza (2 slices)
Never/less than 1 per month 
1 - 3 per month
One per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week 43
45. Which taco filling do you
usually have:
44. Tacos/burritos (1)
Never/less than 1 per month 
1 - 3 per month
One per week
2 - 4 per week





46. Chicken nuggets (6)
Never/less than 1 per month 
1 - 3 times per month
Once per week
2 - 4 times per week






WHAT SPECIFIC BRAND AND TYPE
(LIKE “PARKAY CORN OIL SPREAD”)?
Leave blank if you don’t know.





































      
51. Salami, bologna, or other
deli meat sandwich (1)
50. Roast beef or ham
sandwich (1)
Never/less than 1 per month
1 - 3 per month
One per week
2 or more per week
47
48
52. Tuna sandwich (1)
Never/less than 1 per month
1 - 3 per month
One per week
2 or more per week
Never/less than 1 per month
1 - 3 per month
One per week




48. Peanut butter sandwich (1)
(plain or with jelly, fluff, etc.) 
47. Hot dogs (1)
Never/less than 1 per month
1 - 3 per month
One per week
2 - 4 per week
5 or more per week
49. Chicken or turkey sandwich (1)
Never/less than 1 per month
1 - 3 per month
One per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 per month
One per week
2 or more per week
52
57. Pork or ham as main dish
(1 serving)
56. Beef (steak, roast) or lamb
as main dish (1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
53
54
55. Fresh fish as main dish (1 serving)
55
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
58. Meatballs or meatloaf (1 serving)
61. Spaghetti with tomato sauce
(1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4  times per week
5 or more times per week
56
57
60. Macaroni and cheese
(1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week





6263. Liver: beef, calf, chicken
or pork (1 serving)
Never/less than 1 per month
Less than once per month
Once per month
2 - 3 times per month
Once per week or more
53. Chicken or turkey as
main dish (1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
54. Fish sticks, fish cakes or fish
sandwich (1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
62. Eggs (1)
Never/less than 1 per month
1 - 3 eggs per month
One egg per week
2 - 4 eggs per week




Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
64. Shrimp, lobster, scallops
(1 serving)
Never/less than 1 per month
1 - 3 times per month
Once per week












Never/less than 1 per month
Once per week or less
2 - 6 times per week
Once per day
2 or more times per day
70
70. Clear soup (with rice,
noodles, vegetables) 1 bowl
69. Ketchup
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
71
72
71. Cream (milk) soups or 
chowder (1 bowl)
Never/less than 1 per month
1 - 3 bowls per month
1 bowl per week
2 or more bowls per week
Never/less than 1 per month
1 - 3 bowls per month
1 bowl per week
2 - 6 bowls per week
1 or more bowls per day 73
74. Salad dressing (not
low calorie)
72. Mayonnaise
Never/less than 1 per month
1 - 3 times per month
Once per week




73. Low calorie/fat salad dressing
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 6 times per week
Once or more per day
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 6 times per week
Once or more per day
76
75. Salsa
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 6 times per week
Once or more per day
77
76. How much fat on your






77. When you have chicken or




65. French toast (2 slices) 65
66
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
67
66. Grilled cheese (1) 67. Eggrolls (1)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week








79. Hot breakfast cereal, like
oatmeal, grits (1 bowl)
78. Cold breakfast cereal 
(1 bowl)
Never/less than 1 per month
1 - 3 bowls per month
1 bowl per week
2 - 4 bowls per week
5 - 7 bowls per week
2 or more bowls per day
80. White bread, pita bread,
or toast (1 slice)
Never/less than 1 per month
1 - 3 bowls per month
1 bowl per week
2 - 4 bowls per week
5 - 7 bowls per week
2 or more bowls per day
Never/less than 1 per month
1 slice per week or less
2 - 4 slices per week
5 - 7 slices per week
2 - 3 slices per day
4+ slices per day
82. English muffins or
bagels (1)
81. Dark bread (1 slice)
Never/less than 1 per month
1 slice per week or less
2 - 4 slices per week
5 - 7 slices per week
2 - 3 slices per day
4+ slices per day
83. Muffin (1)
Never/less than 1 per month
1 - 3  per month
1 per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 muffins per month
1 muffin per week
2 - 4 muffins per week
5 or more muffins per week
85. Biscuit/roll (1)84. Cornbread (1 square)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more per week
86. Rice
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
88. Tortilla - no filling (1)87. Noodles, pasta
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
89. Other grains, like kasha,
couscous, bulgurNever/less than 1 per month
1 - 3 per month
1 per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 times per month
Once per week













91. French fries (large order)90. Pancakes (2) or 
waffles (1)
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
92. Potatoes - baked, boiled, mashed
Never/less than 1 per month
1 - 3 orders per month
1 order per week
2 - 4 orders per week
5 or more orders per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week











Never/less than 1 per month 
1 - 3 glasses per month
1 glass per week
2 - 6 glasses per week
1 glass per day
2 or more glasses per day
95. Bananas (1)93. Raisins (small pack) 
Never/less than 1 per month
1 - 3 times per month
1 per week
2 - 4 times per week
5 or more times per week
96. Cantaloupe, melons (1/4
melon)
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 times per month
1 per week
2 or more times per week
98. Pears (1)97. Apples (1) or applesauce   
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 6 per week
1 or more per day
99. Oranges (1), grapefruit (1/2)
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 6 per week
1 or more per day
Never/less than 1 per month 
1 - 3 per month
1 per week
2 - 6 per week
1 or more per day
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
Never/less than 1 per month
1 - 3 per month
1 per week









Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
104. Tomatoes (1) 103. Apple juice and other fruit 
juices (1 glass)
Never/less than 1 per month
1 - 3 glasses per month
1 glass per week
2 - 6 glasses per week
1 glass per day
2 or more glasses per day
105. Tomato/spaghetti sauce
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 6 per week
1 or more per day
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
107. String beans106. Tofu
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
SERIAL #
 100. Strawberries  101. Peaches, plums, apricots (1)
100
101













         
109. Broccoli
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
Once per week or less
2 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
110. Beets (not greens)
111. Corn 112. Peas or lima beans
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once a week
2 - 4 times per week
5 or more times per week
113. Mixed vegetables
114. Spinach 116. Green/red peppers
Never/less than 1 per month
1 - 3 times per month
Once a week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once a week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
117. Yams/sweet potatoes (1) 118. Zucchini, summer squash,
eggplant
115. Greens/kale
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
123. Coleslaw
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
Never/less than 1 per month
Once per week or less










Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 6 times per week
One or more per day




Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
120. Carrots, raw
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week















126. Potato chips (1 small bag)
Never/less than 1 per month
1 - 3 small bags per month
One small bag per week
2 - 6 small bags per week
1 or more small bags per day
Never/less than 1 per month
1 - 3 times per month
Once per week
2 or more times per week
127. Corn chips/Doritos
(small bag)
128. Nachos with cheese (1 serving)
Never/less than 1 per month
1 - 3 small bags per month
One small bag per week
2 - 6 small bags per week
1 or more small bags per day
129. Popcorn (1 small bag)
Never/less than 1 per month
1 - 3 small bags per month
1 - 4 small bags per week
5 or more small bags per week
Never/less than 1 per month
1 - 3 small bags per month
1 - 4 small bags per week
5 or more small bags per week
130. Pretzels (1 small bag) 131. Peanuts, nuts (1 small bag)
Never/less than 1 per month
1 - 3 small bags per month
1 small bags per week
2 or more small bags per week
132. Fun fruit or fruit rollups
(1 pack)
Never/less than 1 per month
1 - 3 packs per month
1 - 4 packs per week
5 or more packs per week
Never/less than 1 per month
1 - 3 times per month
1 - 4 times per week
5 or more times per week
133. Graham crackers 134. Crackers, like saltines or
wheat thins 
Never/less than 1 per month
1 - 3 times per month
1 - 4 times per week










NONE 1 2 3 4 OR MORE
School Days
NONE 1 2 3 4 OR MORE
Vacation/Weekend Days
Between breakfast and lunch
After lunch, before dinner
After dinner
Snacks
125. Fill in the number of snacks (food or drinks) eaten on school
days and weekends/vacation days.
125
Example  If you eat poptarts rarely (about 
6 per year) then your answer should look
like this:
E3. Poptarts (1)
Never/less than 1 per month
1 - 3 per month
1 - 6 per week
1 or more per day












Never/less than 1 per month
1 - 3 donuts per month
1 donut per week
2 - 6 donuts per week
1 or more donuts per day
139. Donuts (1)
135. Poptarts (1)
Never/less than 1 per month
1 - 3 poptarts per month
1 - 6 poptarts per week
1 or more poptarts per day
Never/less than 1 per month
1 - 3 slices per month
1 slice per week
2 or more slices per week
Never/less than 1 per month
1 - 3 per month
Once per week
2 - 6 per week
1 or more per day
136. Cake (1 slice) 137. Snack cakes, Twinkies (1 package)
138. Danish, sweetrolls,
pastry (1)
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 4 per week
5 or more per week
Never/less than 1 per month
1 - 3 cookies per month
1 cookie per week
2 - 6 cookies per week
1 - 3 cookies per day
4 or more cookies per day
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 4 per week
5 or more per week
140. Cookies (1)
141. Brownies (1) 142. Pie (1 slice)
Never/less than 1 per month
1 - 3 slices per month
1 slice per week
2 or more slices per week
Never/less than 1 per month
1 - 3 per month
1 per week
2 - 6 per week
1 or more per day
143. Chocolate (1 bar or packet) 
like Hershey’s or M & M’s
144. Other candy bars (Milky
Way, Snickers)
Never/less than 1 per month
1 - 3 candy bars per month
1 candy bar per week
2 - 4 candy bars per week
5 or more candy bars per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week





Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
Never/less than 1 per month 
1 - 3 times per month
Once per week
2 - 4 times per week
5 or more times per week
148. Frozen yogurt 149. Ice cream
150. Milkshake or frappe (1)
Never/less than 1 per month
1 - 3 per month
1 per week
2 or more per week
Never/less than 1 per month
1 - 3 popsicles per month
1 popsicle per week
2 - 4 popsicles per week






























152. Please list any other foods that you usually eat at least once per week that are not listed (for


















































































































































































































































1 2 3 4 5 6 7 8 9 10 11 12 93 94 95 96 97 98 99
SERIAL #













Respondent : (please check)
Mother
Other
GC 5/03  Copyright 1993, Harvard School of Public Health Continued on next page
1
Children’s Nutrition Questionnaire
What Have You Been Eating Lately?
“During the past 4 weeks, how often did you eat
a serving of each of the foods listed here?”
Mark only one X for each food
Example:
What kind of milk does your child usually drink? (Check one)
1 breastmilk 3 whole 5 1% 7 Chocolate Milk
2 formula 4 2% 6 skim 8 other
last 4
weeks each week each day
Number  of t imes 0 1–3 1 2–4 5–6 1 2–3 4–5 6+
Milk   
Hot  chocola te X
X
0 1 2 3 4 5 6 7 8
last 4
weeks each week each day
Number  of t imes 0 1–3 1 2–4 5–6 1 2–3 4–5 6+
Milk
Hot chocolate
Cheese, plain or in sandwiches
Yogurt
Ice cream (cones, sandwiches, sundaes)
Pudding
0 1 2 3 4 5 6 7 8
last 4
weeks each week each day
Number  of t imes 0 1–3 1 2–4 5–6 1 2–3 4–5 6+
Orange ju ice or  grapefru it  ju ice
Other  ju ice
Fru it  dr inks (Hi-C, Kool-a id, lemonade, spor t sdr ink)
Banana
Peaches
Fru it  cockta il, mixed fru it
Orange or  grapefru it














GC 5/03  Copyright 1993, Harvard School of Public Health
0 1 2 3 4 5 6 7 8
Number  of t imes 4-52-315-62-411-30
last 4
weeks each dayeach week
6+
0 1 2 3 4 5 6 7 8
each dayeach weeklast 4weeks
4-52-315-62-411-30 6+Number  of t imes
Mark only one X for each food.




Tomatoes, tomato sauce, salsa





Greens (mustard, turnip, kale)
Mixed vegetables
Squash, orange or winter
Zucchini, yellow squash
French fries, fried potatoes, tater tots
Potatoes (baked, boiled, or mashed)
Sweet potatoes or yams












Chocola te or  candy bar
Other candy (not chocolate)
Coffee or tea
Soda, soft drink, pop (not sugar free)
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0 1 2 3 4 5 6 7 8
4-52-315-62-411-30 6+Number  of t imes
last 4
weeks each dayeach week
1-30 2-3 4-5 6+15-62-41Number  of t imes
last 4
weeks each dayeach week
0 1 2 3 4 5 6 7 8
3
Beans (baked, chili, or other)
Rice






Hamburger (prepared any way)
Canned tuna
Fried fish, fish sticks
Other fish
Cold cuts (baloney, ham, salami)
Fried chicken, chicken nuggets
Other chicken or turkey
Pork or ham
Roast beef or steak 
Liver, organ meats
Peanut butter
Bread (slice) toast, roll, or pita










Sweet roll or muffin
Pancake, waffle, or french toast









1. What  type of bread does your  ch ild usua lly ea t :
white bread whole whea t  or  dark bread about  ha lf and ha lf DON’T EAT BREAD
1 2 3 4
2. What  type of margar ine does your  ch ild usua lly use:
st ick tub squeeze DON’T USE MARGARINE
1 2 3 4
Is th is margar ine:
corn  oil nonfa t other
1 2 3
3. If your  ch ild ea t s cold breakfast  cerea l, what  type:
h igh  fiber  (eg. All Bran) unsweetened (eg. Corn  F lakes) sweetened (eg. Cap’n  Crunch)
1 2 3
4. Does your  ch ild take a  mult i-vitamin  pill (F lin t stones, Tr iViFlor ): 
no yes
0 1
If yes, how often :
Every day 4–6 t imes a  week 1–3 t imes a  week Less than  one t ime a  week
1 2 3 4
5. Does your  ch ild take a  separa te iron  pill (not  in  the mult i-vitamin  pill above): 
no yes
0 1
6. Does your  ch ild take a  separa te fluor ide supplement  (not  in  the mult i-vitamin  pill above): 
no yes
0 1
7. Does your  ch ild ea t  fr ied food a t  home: 
no yes
0 1
If yes, how often :
Every day 4–6 t imes a  week 1–3 t imes a  week Less than  one t ime a  week
1 2 3 4
If yes, what  type of fa t  do you  use to fry a t  home:
but ter margar ine cr isco corn  oil canola  oil olive oil other  vegetable oil
1 2 3 4 5 6 7
8. Do you  bake cookies, cake or  pies a t  home: 
no yes
0 1
If yes, how often  does your  ch ild ea t  home-baked cookies, cake or  pies?
Every day 4–6 t imes a  week 1–3 t imes a  week Less than  one t ime a  week
1 2 3 4
If yes, what  type of fa t  do you  use to bake a t  home:
but ter margar ine cr isco corn  oil canola  oil olive oil other  vegetable oil
































*Values reported are the Acceptable Macronutrient Distribution Range (AMDR.) 
 The AMDR is the range of intake for a particular energy source that is associated  
with reduced risk of chronic disease while providing intakes of essential nutrients. 
If an individual consumed in excess of the AMDR, there is a potential of increasing  
the risk of chronic diseases and insufficient intakes of essential nutrients. 
 
 
RDA, EAR, UL for Antioxidant Nutrients 
 Vitamin C mg Vitamin E mg Zinc mg 







1-3 years                                 15 (13) 400   6 (5) 200 3 (2.5) 7 
4-8 years 25 (22) 650   7 (6) 300 5 (4) 12 
9-13 years 
                   Male 



















14-18 years  
                   Male 





















RDA, EAR, UL for B6, B12, Folate 
 Folate mcg B6 mg B12 mcg 
Age Group  RDA (EAR) UL RDA (EAR) UL RDA (EAR) UL 
1-3 years                                      150 (120)  300       .5  (.4) 30 150 (120) ND 
4-8 years      200 (160) 400       .6 (.5) 40 200 (160) ND 
9-13 years 
                   Male 
                 Female 
 
     300 (250) 





      1.0 (.8) 









14-18 years  
                   Male 
                Female  
          
     400 (330) 





     1.3 (1.0) 















Age Group  Fat* 




(% of Calories) 
    
1-3 years                                   30-40% 5-20% 45-65% 
4-8 years 25-35% 10-30% 45-65% 
9-13 years                  25-35% 10-30% 45-65% 








RDA, EAR, UL for Pantothenic Acid, Riboflavin, Thiamin   
 Pantothenic Acid mg Thiamin mg 
 
Riboflavin mg  
Age Group  RDA (EAR) UL RDA (EAR) UL RDA (EAR) UL 
1-3 years                                 2* ND        .5 (.4) ND        .5 (.4) ND 
4-8 years         3*    ND        .6 (.5) ND       .6 (.5) ND 
9-13 years 
                   Male 
                 Female 
 
        4* 




       .9 (.7) 




      .9 (.7) 
      .9 (.7) 
 
ND 
14-18 years  
                   Male 
                Female  
 
        5* 




      1.2 (1.0) 




      1.3 (1.0) 
      1.0 (.9) 
 
ND 
*AI=Adequate Intake; ND = Not Determined 
 
 
RDA, EAR, UL for Niacin mg 
Age Group  RDA (EAR) UL 
1-3 years                                      6 (5)  10 
4-8 years      8 (6) 15 
9-13 years 
                   Male 
                 Female 
 
     12 (9) 




14-18 years  
                   Male 
                Female  
          
     12 (12) 







RDA, EAR, UL for Bone Metabolizing Nutrients 
 Calciummg Vitamin D IU 
 
Vitamin K mcg 
 
Age Group  RDA (EAR) UL RDA 
(EAR) 
UL RDA UL  
1-3 years                                   700 (500) 2,500  600 (400) 2,520 30* ND 
4-8 years 1,000 (800) 2,500  600 (400) 3,000 55* ND 
9-13 years 
                   Male 








 600 (400) 









14-18 years  
                   Male 








 600 (400) 




















E. Summary Tables of NHANES  









2-5 years  
Male 

















                   Male 
















12-19 years  
                   Male 


















Age Group Vitamin C mg 
 




2-5 years  
Male 











                  Male 










12-19 years  
                  Male 











Age Group Calcium mg 
 
Vitamin D IU 
 
Vitamin K mcg 
 
2-5 years  
Male 











                Male 










12-19 years  
                Male 















































2-5 years  
Male 






















              Male 





















12-19 years  
              Male 













































F. Nutrient Mean Intakes for B Vitamins  
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
 
 
 
 
 
 
 
